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ABSTRACT

THE ROLE OF NICOTINE, a7 NICOTINIC ACETYLCHOLINE RECEPTORS
AND EXTRACELLULAR MATRIX REMODELING IN PULMONARY FIBROSIS

Glenn Ward Vicary

November 22nd, 2016

The median survival for idiopathic pulmonary fibrosis (IPF) patients from
diagnosis is a dismal 3 years. This condition is characterized by pulmonary
fibroproliferation and excess production and disordered deposition of extracellular
matrix (ECM) proteins resulting in obliteration of the original tissue architecture,
loss of lung function and eventual death due to respiratory failure.
The main hindrance to the development of effective treatments against
pulmonary fibrosis is the late detection of its progression and is often of unknown
cause. Tobacco smoke represents the most important environmental factor linked
to the development of pulmonary fibrosis, with over 60% of IPF patients current or
ex-smokers, yet exactly how tobacco influences lung injury and repair is unknown.
Research in this area has been hampered by the fact that tobacco is a very
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complex substance, containing thousands of chemicals. Due to this complexity, I
have pursued a different approach and focused on factors, specifically nicotine,
which might render the lung susceptible to fibrosis and contribute to the early
pathophysiology of IPF.
In this dissertation, I extend the work of Dr. Jesse Roman’s lab to investigate
additional extracellular matrix modifications via nicotine exposure, including
collagen type I. Investigating the cellular receptors and molecular mechanisms
mediating the effects of nicotine on fibroblast collagen production/deposition and
the potential role of nicotine-induced remodeling in rendering the host susceptible
to pulmonary fibrosis are explored through 5 chapters: 1) The effects of nicotine
on lung fibroblast proliferation and collagen expression/deposition in vitro and in
vivo, and the cholinergic receptors responsible for these effects. 2) The effects of
chronic nicotine exposure on injury-induced fibrosis. 3) The impact of chronic
nicotine exposure on survival after bleomycin-lung injury. 4) A new diagnostic
physiological formula for earlier detection of pulmonary fibrosis progression in IPF
patients. 5) A clinical review on Hermansky-Pudlak syndrome, an orphan disease
characterized by the natural formation of pulmonary fibrosis. This work provides a
detailed understanding of the mechanisms by which tobacco promotes lung
remodeling, leading to the development of better tools for diagnostic tracking, care
and treatment of these patients.
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CHAPTER I

BACKGROUND AND INTRODUCTION

1.1 Overview

The lung is a dynamic organ, constantly expanding and contracting while
being exposed to environmental and chemical challenges. To handle these insults,
the lung readily repairs itself against a range of antigens and environmental
pathogens. Correct lung repair allows for normal lung function, but when disrepair
occurs, a variety of diseases can occur, including idiopathic pulmonary fibrosis.
Lung remodeling caused by disrepair is often drastic, affecting protein composition,
lung structure, elasticity, and oxygen diffusion, making it progressively difficult for
patients to do even basic activities such as walking and talking.

1.2 Prevalence of Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis (IPF) is a chronic disease that affects over
100,000 Americans [1]. The median survival for patients from diagnosis is a dismal
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3 years [2]. IPF is usually diagnosed in older patients, with more than 85% of
patients over 50 years old and an increased prevalence in males [2-9].
Surprisingly, the number of IPF cases appears to be increasing; likely due to the
aging population, increased patient and physician awareness of IPF and improved
computerized tomography (CT) imaging [10].
IPF is classified as an interstitial lung disease (ILD), which is an umbrella
term for a large group of pulmonary disorders characterized by progressive
remodeling of pulmonary tissue. ILDs are characterized by known and unknown
causes, consisting of over 200 diseases including sarcoidosis and idiopathic
interstitial pneumonias (IIPs). IIPs are subclassified based on histological
appearance, with the most common and severe form of IIP being IPF; which
accounts for 20-30% of ILDs (Figure 1) [11, 12]. IPF is diagnosed by exclusion of
other diseases when there is evidence of impairment of lung function and presence
of a histopathological pattern of usual interstitial pneumonia (UIP).

1.3 Causes of IPF

Environmental factors (e.g., allergens, tobacco), occupational exposures
(e.g. asbestos and silica exposure), genetic factors (e.g. surfactant-related
proteins, telomerase, HPS) and viral factors (herpesvirus) have been associated
with the development of pulmonary fibrosis, but its etiology can be elusive [1, 1317].
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Figure 1. Classifying Interstitial Lung Diseases
Reprinted with permission from Nature Publishing Group. [Nat Rev Drug Discover] (du Bois, R.M., Strategies for treating
idiopathic pulmonary fibrosis, 2010. 9, p. 124-140) Copyright 2010
License #: 3972681241289

Idiopathic pulmonary fibrosis is classified as an interstitial lung disease, which is
an umbrella term for a large group of pulmonary disorders characterized by
progressive remodeling of pulmonary tissue. Interstitial lung diseases can be
subdivided into four broad categories based on histological appearance. Idiopathic
pulmonary fibrosis is the most lethal ILD and its diagnosis depends on the
exclusion of other diseases.
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Underlying amplifying factors like aging and epigenetic changes are thought to
influence the progressive nature of pulmonary fibrosis [18]. Most cases of IPF are
sporadic with 4% of patients being familial [19-22]. The familial form of IPF tends
to present at a younger age when compared with the more common idiopathic
form.

1.4 Tobacco and Nicotine

Of all the environmental risk factors, tobacco smoke represents a major
factor linked to the development of IPF, with over 60% of IPF patients being current
or ex-smokers [1, 23-25]. However, studying the role of tobacco in IPF has been
hampered by the complex nature of tobacco smoke, which contains over 7,000
chemicals [26, 27]. Due to the complexity of tobacco, attention has recently turned
to the potential role of nicotine in mediating the effects of tobacco smoke.
Nicotine is an alkaloid present in tobacco and represents ~0.6–3.0% of the
dry weight of tobacco and is known for driving the addictiveness of cigarettes.
Nicotine’s unique properties allow 30% of it to be instantly absorbed and reach the
brain within 7 seconds [28, 29]. Studies have shown smokers to have average
nicotine levels of 10-50 ng/ml (0.3 µM) in blood plasma [30]. The metabolism of
nicotine varies between species, with a plasma half-life of 2 hours in humans and
approximately 6-7 minutes in mice [30]. In humans, the metabolism rate of nicotine
is affected by age, race, and gender. Women and younger smokers have been
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reported to metabolize nicotine quicker [31, 32]. Additionally, caucasians cleared
nicotine more rapidly than Asians and African Americans [30].
Nicotine not only drives addiction, but affects several biological processes,
including cell proliferation, apoptosis, migration, invasion, angiogenesis,
inflammation and immunity [33]. Additional studies have unveiled that nicotine also
affects lung development through increased branching and increasing nAChR
expression [34, 35]. Thus, it appears that nicotine is not just responsible for
tobacco dependence, but might also contribute to the pathogenesis of tobaccorelated disorders, including IPF.

1.5 Mechanisms of Idiopathic Pulmonary Fibrosis

The exact mechanisms which contribute to the development of IPF are
unknown. However, current models of pulmonary fibrosis pathogenesis indicate
epithelial cell apoptosis and dysfunction, likely type I alveolar epithelial cells
(AECs), as the inciting cause of IPF [36]. Type I AECs are believed to control
pulmonary structural mesenchymal cells through the secretion of various
mediators and cell–cell contact [37]. When injured, type I AECs are thought to
signal type II AECs to undergo hyperplastic proliferation to cover the exposed
basement membranes. After normal repair, the hyperplastic type II AECs will
undergo regulated apoptosis and any remaining cells will differentiate to become
type I AEC [38-40]. In contrast, disrepair leads to scar tissue formation, which is
usually self-limited, but can become progressive, with ongoing lung parenchymal
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destruction and replacement by pathologic fibrosis with the activation of fibroblasts
(Figure 2).
Under these conditions of disrepair, Transforming Growth Factor-b (TGFb) stimulation may activate fibroblasts to differentiate into a-smooth muscle actin
(a-SMA) expressing myofibroblasts [18, 36, 41]. The origins of these fibroblasts
(myofibroblasts) are unclear, but combinations of mechanisms are hypothesized,
including the transdifferentiation of epithelial cells (epithelial-mesenchymal
transformation (EMT)), the differentiation of fibrocytes and stem cells, and the
proliferation of resident fibroblasts [42-44].
Regardless of the source of origin, the interplay between dysfunctional
epithelial cells and activated myofibroblasts seems to drive unrestrained collagen
deposition and tissue scarring ‘fibrotic foci’, resulting in obliteration of the original
architecture, loss of lung function and, eventual death due to respiratory failure
(Figure 3) [45-48]. In IPF patients, areas of AEC apoptosis and foci of a-SMApositive myofibroblasts were detected together, consistent with the mechanism
proposed above [49].

1.6 Diagnosis and Management of IPF

There is no cure for IPF, so treatment focuses on slowing the progression
of fibrosis and improving patient quality of life. Avoidance of cigarette smoke and
other pulmonary irritants is critical with daily exercise recommended to avoid
deconditioning. Recently, the FDA has approved two drugs for IPF treatment,
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Pirfenidone and Nintedanib [50-53]. It should be emphasized that these drugs are
not curative, but instead appear to slow down progression in IPF. Also, the
effectiveness of these drugs in other conditions resulting in pulmonary fibrosis has
not been studied, thus, current interventions for pulmonary fibrosis remain
suboptimal. Pirfenidone is a small molecular TGF-b inhibitor, whereas Nintedanib
is a tyrosine kinase inhibitor that targets various growth factor receptors including
platelet derived growth factor (PDGF), fibroblast growth factor (FGFR) and
vascular endothelial growth factor (VEGF) receptors [50, 52, 54]. These drugs also
have undesirable side effects, so supportive therapy is an additional approach to
management of IPF. Additional therapies include supplemental oxygen for
hypoxemia, pulmonary rehabilitation and lung transplantation in appropriate
candidates.
The main hindrance to the development of effective treatments against
pulmonary fibrosis is due to late diagnosis. For this reason, efforts should be
directed at novel therapeutics for prevention of lung remodeling or early detection
through the identification of specific early biomarkers of disease. It is for this
reason that I have pursued a different approach and focused on the factors
that render the lung susceptible to fibrosis and contribute to the early
pathophysiology of IPF, which might help gain insight into the overall
mechanisms that lead to the development of this disease and the factors that
regulate its progression.
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Figure 2. Proposed Events of Idiopathic Pulmonary Fibrosis
Reprinted with permission from The Company of Biologists Ltd. [Dis. Model. Mech.] (Kropski J. A. et Al., Genetic studies
provide clues on the pathogenesis of idiopathic pulmonary fibrosis, 2013. 6(1): p. 9-17) Copyright 2012
Reproduction Lic# https://creativecommons.org/licenses/by-nc-sa/3.0

Various genetic factors and environmental exposures produce a ‘vulnerable’
alveolar epithelial cell (AEC) population. Exposure to a secondary recurrent or
persistent injury leads to enhanced AEC apoptosis, as well as aberrant activation
of stress response pathways. Ongoing type II AEC dysfunction leads to scar
formation and progressive loss of lung architectural complexity. This culminates
into progressive fibrotic pulmonary tissue remodeling.
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Pulmonary Fibrosis

Normal Lungs

Fibroblastic Foci

Figure 3. Fibroblastic Foci in Idiopathic Pulmonary Fibrosis
Copyright Permissions not required for this type of use. (Lederer, D., A new era in IPF: Diagnosing Idiopathic Pulmonary
Fibrosis) http://www.pilotforipf.org/ipf-resources/slide-library

Idiopathic pulmonary fibrosis is characterized by unrestrained collagen deposition
and tissue scarring from fibroblasts, forming ‘fibrotic foci’, resulting in obliteration
of the original extracellular matrix as seen here in histological staining by
hematoxylin and eosin staining.
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1.7 Lung Extracellular Matrix

Extracellular matrix remodeling is the main characteristic of pulmonary
fibrosis. The extracellular matrix (ECM) was historically believed to be a noncellular scaffolding of fibrous proteins, glycoproteins and proteoglycans for cells to
adhere, but recent research has shown that the ECM plays many crucial roles in
homeostasis and disease [55]. Now, the ECM is known to affect important
biochemical and biomechanical signaling between cells, including cellular
differentiation [56].
The pulmonary ECM consists of basement membranes and the interstitial
spaces. These basement membranes are found under epithelial and endothelial
cells which form the interstitial spaces of the parenchyma [57]. Within this
interstitium is where fibroblasts, which are mainly responsible for ECM production,
reside. The ECM of murine and human lungs have been characterized, showing
the majority of the matrisome is conserved [58, 59]. Under homeostatic conditions,
the ECM is tightly regulated for normal development and wound healing.
Alterations in pulmonary ECM are suspected to play a role in disorders affecting
all lung compartments (airways, vessels, alveolar units), including IPF, Chronic
Obstructive Pulmonar Disease (COPD) and sarcoidosis.
Fibronectin is an ECM glycoprotein highly expressed in injured tissues, and
is considered a sensitive marker of tissue injury and activation of tissue remodeling
[60-62]. In the injured lung, fibronectin is deposited over denuded basement
membranes where it is thought to support the migration of alveolar epithelial cells
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during repair [61]. It promotes the proliferation of fibroblasts, aids in the deposition
of collagen, stimulates the chemotaxis of monocytes and other immune cells and
induces cytokine production in macrophages [63-69]. Excessive fibronectin
deposition, however, has been hypothesized to promote disrepair [70]. Fibronectin
expression and fibroproliferation were increased in the lungs of smokers [71-74].
Also, clinical studies have shown increased fibronectin content within the
bronchoalveolar lavage fluid of smokers [75].
Fibrillar collagen is another matrix component highly expressed in lung
tissues during injury and repair, and its expression signals activation of more
permanent tissue remodeling. Collagen type I is the most common form of collagen
in the human body and is highly abundant within connective tissues, including
tendon, ligament, skin, and lung tissue. Each rope-like procollagen molecule is
made up of three chains: two pro-α1 (I) chains, which are produced from
the COL1A1 gene, and one pro-α2 (I) chain, which is produced from the
COL1A2 gene. After processing, the resulting mature collagen molecules arrange
themselves into long, thin fibrils. Individual collagen molecules are then crosslinked to one another within these fibrils, thereby forming strong collagen fibrils
[76].
These ECM proteins, together with proteoglycans and other matrix
components compose the acellular structure of the lung. The controlled deposition
and turnover of these ECM proteins is essential for maintaining tissue integrity.
Alterations in these processes lead to aberrant tissue remodeling and fibrotic lung
diseases.

11

1.8 Transitional Remodeling

The connection between nicotine and tissue remodeling seen in pulmonary
fibrosis has yet to be completely elucidated. To date, there are no data suggesting
nicotine, alone, can promote pulmonary fibrosis. The Roman lab has previously
shown that nicotine exposure induces fibronectin deposition by pulmonary
fibroblasts. Additionally, increased fibronectin deposition was detected in the lungs
of animals chronically exposed to nicotine, but without overt alterations in overall
lung architecture [77].
Instead, this dissertation provides evidence of a process termed transitional
remodeling, which might precede the dramatic tissue alterations and potentiate
pulmonary fibrosis progression. Transitional remodeling is defined as subtle
alterations in the ECM composition deposition and assembly, including fibronectin
and collagen, without causing overt change in tissue architecture. Nicotine
exposure induces transitional remodeling, but this could be reversible and, in fact,
in most injuries, the body may undergo transitional remodeling as part of the
normal wound healing process. As such, the body returns to normal. However, the
implications of transitional remodeling in disrepair are not fully understood. If the
lung experiences a second hit (e.g. bleomycin), transitional remodeling may render
the host susceptible to disrepair through the pro-inflammatory effects of matrix
fragments and by its ability to promote the deposition of other more permanent
ECM proteins (Figure 4) [78].
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1.9 Nicotinic Acetylcholine Receptors (nAChRs) in Lungs

As presented above, nicotine promotes transitional remodeling. However,
the mechanisms involved in this process are unclear. Nicotine interacts with the
body through receptors capable of signal transduction termed nicotinic
acetylcholine receptors (nAChRs) (Figure 5) [79, 80]. nAChRs are a family of
multimeric acetylcholine-triggered cation channel proteins that form the excitatory
neurotransmitter receptors on muscles and nerves in the peripheral nervous
system. In addition to the nervous system, nAChRs have been found in
lymphocytes [81], leukocytes [82], monocytes [83], keratinocytes [84], and NIH3T3
fibroblasts [85]. These receptors are pentameters made up in homomeric and
heteromeric fashion. The homomeric (a7)5 is the most common nAChR, containing
five a7 subunits and is the most abundant homomeric form in the body. Binding of
a ligand (acetylcholine/nicotine) leads to depolarization of the membrane and
generation of an action potential that spreads along the surface of cell membranes.
Evidence of a3, a5, a7 nAChR subunits has been detected in both human
and mouse bronchial epithelial cells [86]. a7 nAChRs have been detected in airway
epithelial cells of developing primate lungs around large airways and blood
vessels, free alveolar macrophages, alveolar type II cells and pulmonary
neuroendorcrine cells [34].
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Figure 4. Transitional Remodeling of the Lung Extracellular Matrix (ECM)
Copyright Permissions not required for this type of use. (Adapted from Poole, L. and Arteel, G., Transitional Remodeling
of the Hepatic Extracellular Matrix in Alcohol-induced Liver Injury) https://www.hindawi.com/journals/bmri/aip/3162670/

Nicotine exposure induces ECM proteins and subclinical remodeling forming a
transitional extracellular matrix. This transitional matrix, while it causes no
detrimental changes in the lung, may contribute to disrepair and inflammation after
injury. If the insult is removed, the transitional matrix may resolve back to a normal
state. Exposure to a secondary injury may progress to a fibrotic matrix via
increased ECM synthesis and blunted ECM degradation, ultimately leading to
pulmonary fibrosis.
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Figure 5. Structure of Nicotinic Acetylcholine Receptors
Reprinted with permission from Nature Publishing Group. [Oncogene] (Improgo, M.R., From smoking to lung cancer: the
CHRNA5/A3/B4, 2010. 29, p. 4874-4884) Copyright 2010
License #: 3991471282111

Nicotinic Acetylcholine Receptors (nAChRs) are a family of multimeric
acetylcholine-triggered cation channel proteins that form the excitatory
neurotransmitter receptors on muscles and nerves in the peripheral nervous
system. (A) Schematic representation illustrating the pentameric arrangement of
subunits in an assembled nAChR. (B) Conserved domains of a nAChR subunit
including the amino (N) and carboxy (C) terminals, transmembrane segments
(M1–M4) and the intracellular loop. (C) Assembly of heteromeric and homomeric
nAChR subtypes. Individual nAChR subunits are represented as colored circles,
with diamonds representing ligand-binding sites. Pentagons in the center of each
pentamer represent the pore region, which is selective for cations (e.g. Calcium).
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The role of nAChRs in the lung is largely unknown. Acetylcholine is
produced by several non-neuronal lung cells as a regulator of bronchomotor tone
and mucus secretion from airway submucosal glands in lungs. Nicotine-nAChR
interactions can affect lung development and ECM deposition. Dr. Roman’s lab
has demonstrated that nicotine induces fibronectin expression in lung fibroblasts
via a7 nAChRs [77]. This increase in matrix proteins suggests that nicotine might
induce myofibroblastic features in lung fibroblasts, which has been associated with
pulmonary fibrosis [87]. Dr. Elliot Spindel’s group has published articles showing
a7 nAChR expression was increased in animals exposed to nicotine, correlating
with increased tissue remodeling (collagen deposition) in surrounding large
airways and vessels [77, 88-94]. Nicotine-a7 nAChR interactions also influence
lung branching morphogenesis and result in airway thickening and dysfunction [34,
35, 91].

1.10 The Role of MEK-1/Erk pathway in mediating nAChR signaling

The intracellular pathways by which nicotine-nAChR interactions promote
lung tissue remodeling are not fully characterized. Fibroblasts from IPF patients
show sustained mitogen-activated protein kinase (MAPK) induction and activation,
a downstream target of the MEK-1/Erk pathway [95, 96]. Fibrotic agents, like
crystalline silica and asbestos, promote activation of MEK-1, which increases the
level of pro-inflammatory cytokines [97]. MEK-1/Erk also induces tumor necrosis
factor-a (TNF-a) through the pro-fibrotic growth factor TGF-b [98].
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As a proof of concept for clinical targeting, a MEK inhibitor prevented TNFa induction and even reversed existing TGF-b-induced lung fibrosis [99].
Additionally, a different MAPK/Erk inhibitor prevented bleomycin-induced fibrosis
[100]. No studies have been published on the effects of MEK-1 inhibition in
humans. MEK-1/Erk could provide a future clinical target for preventing nicotine
induced lung changes.

1.11 Nicotine and Inflammation

In addition to ECM, the regulation of the immune system is a critical
physiological process during pulmonary development, healing, trauma, or
infection. Controlled production of cytokines, such as interleukins (ILs) and TNF-a
induce beneficial inflammatory responses that promote local coagulation to confine
infection and tissue damage [101]. However, unrestricted production of these
cytokines can cause more damage than the original injury.
Acetylcholine is an important neurotransmitter that controls the production
of

pro-inflammatory

cytokines.

Acetylcholine

(endogenous)

and

nicotine

(exogenous) can either bind to muscarinic receptors, which are G-protein-coupled
receptors, or nAChRs, which are ligand-gated ion channels [102].
How nicotine affects inflammation is still being elucidated. nAChRs are
believed to induce different inflammatory responses based on receptor affinities in
multiple immune cell types [103-107]. a7 nAChR ligands (acetylcholine and
nicotine) are normally considered anti-inflammatory due to activation of the
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cholinergic anti-inflammatory pathway. Nicotine has been shown to reduce proinflammatory cytokine expression in monocytes [108]. Interestingly, nicotine is
more specific than acetylcholine at inhibiting the production of pro-inflammatory
cytokines from macrophages and monocytes and this appears to be a7 nAChR
specific [101, 109-111]. Additionally, an a7 agonist PNU-282987 was used in a
murine model of LPS-induced acute lung injury reduced neutrophil recruitment and
IL- 1b, TNF-a, IL-6 and IL-10 cytokine levels in the bronchoalveolar lavage fluid.
In addition, the frequency of M1 macrophages suggests a change in the
macrophage profile [112]. Nicotine can also affect immune cell function, inhibiting
phagocytic activity in neutrophils while enhancing neutrophil elastase release
without affecting superoxide production [113, 114]. Additionally, nicotine induces
neutrophil traps, which can contribute to tissue damage and inflammation [115].
Thus, nicotine-a7 nAChR interactions appears to directly decrease inflammation
in certain cells, but systemic exposure and indirection activation still need to be
investigated.

1.12 Fibrosis and Inflammation

Pulmonary fibrosis has traditionally been considered related to extensive
ECM remodeling with subdued inflammation, but more recent research connects
innate and adaptive immune responses to fibrogenesis. TGF-b1 is considered a
central mediator in pulmonary fibrosis and is the most studied soluble mediator in
addition to playing a central role in promoting EMT [116, 117]. Additionally,
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activated fibroblasts are highly responsive to additional growth factors/proinflammatory cytokines (IL-1b, IL-6, IL-13, IL-33, TNF-a, and interferon-g (IFN-g))
which enhance TGF-b1-induced EMT [118, 119]. IL-1b is a primary inflammasome
cytokine produced by a variety of cells, including activated macrophages, dendritic
cells, neutrophils, and epithelial cells and fibroblasts. It has been shown to
contribute to the progression of adenoviral-induced pulmonary fibrosis and
bleomycin-induced pulmonary fibrosis [120, 121].
Although several cytokines have been associated with IPF progression, the
involvement of each individual immune cells is more complex. Recent studies have
re-ignited the interest into the potential role of inflammation in lung fibrosis and
have implicated t cells, neutrophils, alveolar macrophages, and other cells capable
of releasing the important cytokine regulating mediators, potentially regulating IPF
progression (IFN-g, IL-2, TNF-b, IL-4, IL-5, IL-6, IL-9, IL10, IL-13) [122-128].
In addition to cytokines and soluble mediators, immune cells and fibroblasts
can alternatively be activated by integrins, which can directly interact with the ECM
[129]. Some integrins include aIIbb3 (fibrinogen receptor), aVb3 (vitronectin
receptor), a2b1 (collagen receptor), a5b1 (fibronectin receptor), and a6b1 (laminin
receptor) [130]. This dissertation focuses mainly on collagen type I, because type
I makes up 90% of all collagen in the body. The a2b1 integrin is the main receptor
that interacts with collagen [131, 132]. Collagen has been found to induce M2
macrophages (Th2 response), feeding a feedback loop between fibroblasts and
macrophages, promoting fibrotic responses to lung injury [133-135]. Expression
levels of integrins also seems to play a role in fibroblastic response, with low a2b1
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integrin expression enhancing the proliferation of fibroblasts from patients with IPF
[136].

1.13 Anti-Oxidants

In the lung, another line of protection against the constant exposure to
environmental chemicals and oxidants is a high concentration of anti-oxidants.
When the tightly regulated balance of oxidants and anti-oxidants becomes altered,
this state is referred to as oxidative stress [137]. Oxidant stress can be generated
through many pathways including the generation of nitrogen and reactive oxygen
species (ROS), alterations in Nox expression, and mitochondrial dysfunction [138].
ROS include superoxide, hydrogen peroxide and hydroxyl radicals, and cause
unspecific damage to cells and extracellular matrix [139].
Anti-oxidants are the main line of defense against oxidative damage in the
lung (Figure 6). These include superoxide dismutases (SODs), catalase,
glutathione peroxidase, glutathione S-transferase, and thioredoxin. The SOD
family catalyzes superoxide radicals into hydrogen peroxide and oxygen in a first
order reaction. There are three mammalian SODs: cytosolic (SOD1), mitochondrial
(SOD2), and extracellular (SOD3) [140-142]. The major intracellular SOD is SOD1,
which is a 32-kD copper and zinc containing homodimer (also called Cu/Zn SOD)
present in the cytoplasm and nucleus [143]. SOD2 (MnSOD) contains a
manganese 93-kD homotetramer and is synthesized in the cytoplasm to be
translocated to the inner matrix of mitochondria [141, 144]. SOD2 seems to play a
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role in neurodegenerative diseases [145]. SOD3 (EC-SOD) is the last mammalian
SOD to be discovered and is primarily extracellular [142].
Acute and chronic forms of lung injury, including those associated with
pulmonary fibrosis, are associated with oxidant stress [146]. BAL fluid from IPF
patients showed increased levels of 8-isoprostane, a biomarker of oxidative stress
[147]. Additionally, higher levels of oxidants (e.g. ELF myeloperoxidase,
superoxide, hydrogen peroxide, iNOS) were detected in IPF patients, further
suggesting a role for oxidant stress. [148-150].
With tobacco smoke being the main risk factor for IPF, some have
postulated that cigarette smoke might promote tissue fibrosis through the induction
of oxidant stress, yet the role of nicotine in this process is unclear [146]. In rats,
nicotine has been shown to affect the oxidative state of the lung by increasing the
activity of superoxide dismutase, an important protective mechanism in lung [151,
152]. Overexpression of superoxide dismutase was protective against fibrosis in
the bleomycin model [153].
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Figure 6. Oxidative Stress in IPF
Reprinted with permission from American Thoracic Society. [Am J Respir Crit Care Med] (Kinnula V.L. et Al., Oxidative
stress in pulmonary fibrosis, 2005. 172(4): p. 417-422) Copyright 2005

Anti-oxidants are the main line of defense against oxidative damage in the lung.
Exogenous and endogenous irritants in IPF create a redox imbalance, resulting in
the production of ROS, which potentiate pulmonary fibrosis. Shown are
endogenous antioxidants and the steps at which they can protect the lung from the
effects of ROS. a1PI = a1-proteinase inhibitor; a2M = a2-macroglobulin;
CuZnSOD = SOD1; ECSOD = SOD3; eGPx = extracellular glutathione peroxidase;
GPx = glutathione peroxidase; HO-1 = heme-oxygenase 1; MnSOD = SOD2; TIMP
= tissue inhibitor of metalloproteinases.
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1.14 Modeling Pulmonary Fibrosis

IPF occurs without cause in the majority of patients, making it difficult for
science to develop relevant animal models that resemble human disease. Several
models have been used to study pulmonary fibrosis, yet none can accurately
recapitulate IPF. Fibrosing lung disease occurs naturally in a variety of animals
including horses, cats, donkeys, and dogs (e.g. Westie Terriers) [154-158].
Although these are considered to have pulmonary fibrosis, the similarities between
animal and human disease still need to be elucidated and, thus, they are difficult
to use for research due to a myriad of issues including physiological differences,
genetics, prevalence and cost [159].
More commonly, inducible models of pulmonary fibrosis are utilized.
Bleomycin-induced pulmonary fibrosis is the most commonly used model to
investigate the mechanisms that lead to tissue remodeling after lung injury [160].
Bleomycin has been used as an anti-cancer agent, as it is a glycopeptide
antineoplastic agent derived from Cu(II)complexes from bacterium Streptomyces
verticillus. Bleomycin is effective towards reducing or inhibiting the growth of
neoplasias by degrading cellular DNA with single- and double-strand breaks. This
is due to a DNA-binding and iron-binding site. Bleomycin forms a complex with
iron, causing the iron to oxidize, therefore, reducing oxygen into free-radicals. The
free-radicals cause single- and double-strand DNA breaks, leading to apoptosis,
which is useful in causing damage to cancer cells. An unwanted side effect of
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bleomycin treatment, however, is the development of pulmonary fibrosis due to low
abundance of the inactivating enzyme, bleomycin hydrolase, in the lung [161-163].
Physiologically, intratracheal bleomycin instillation elicits an acute
pneumonitis characterized by the infiltration of the lung with immune cells within
the first week. After the second week, inflammation subsides and the fibrotic stage
of lung injury begins to form with the activation of tissue remodeling genes
including fibronectin, collagens and TGF-b [164-166]. This phase is characterized
by modification of the original lung architecture and formation of pulmonary fibrosis
(Figure 7).
Today, bleomycin is considered one of the best animal models to studying
lung fibrosis due to several similarities with the human disease. IPF and bleomycininduced lung fibrosis share activation of (M2) macrophages, EMT, and microMRNA 21 induction [167-170]. One of the main drawbacks of the bleomycin model
is the changing conditions between the different stages and the fact that the
fibrosis is reversible [171]. Additionally, there is absence of hyperplastic type II
AECs [172].
The bleomycin model has provided some insight into the role of tobacco
exposure in pulmonary fibrosis, with cigarette smoke exposure enhancing alveolar
architecture derangements in hamsters and guinea pigs [173-175]. However,
cigarette exposure failed to enhance bleomycin-induced lung fibrosis in rats, but
the exposure was not initiated till post bleomycin [176]. Thus, there appears to be
a role for tobacco exposure in pulmonary fibrosis, but much remains to be
elucidated.
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Figure 7. Bleomycin-Induced Model of Pulmonary Fibrosis
Vicary, Unpublished.

Bleomycin elicits an acute pneumonitis characterized by early infiltration of the lung
with immune cells within the first week. In addition to inflammation, there is
activation of tissue remodeling genes including fibronectin, collagens, and profibrotic TGF-β. Two weeks after bleomycin instillation, inflammation subsides and
a fibrotic stage of lung injury begins to form after the second week. This phase is
characterized by modification of the original lung architecture and replacement with
fibrosis, shown here with Masson’s tri-chrome staining.
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1.15 Mechanobiology

The lung is one of the few organs constantly expanding and contracting.
How pulmonary fibrosis affects the mechanobiology of the lung and vice versa has
only recently been investigated. Tissue forces were proposed to regulate tissue
remodeling over a century ago, but it has taken modern research technology to
begin to explore the relationship between mechanical forces and cellular behavior.
Recent research has demonstrated that most eukaryotic cells can interact with the
ECM and generate intracellular forces that affect cellular stiffness [177],
cytoskeletal dynamics [178], cell migration [179-181], differentiation [182, 183] and
drug response [184]. Cells can sense changes in the tensile strength and elastic
recoil of the lung, which is determined by fibrillary proteins, such as collagens and
fibronectins [185, 186].
During homeostasis, the turnover of ECM proteins varies greatly, which can
alter the ECM stiffness [187]. Collagen fibers are estimated to remodel at 3-10%
per day, whereas elastin fibers, another ECM protein, are life-long, surviving
approximately 74 years [188, 189]. Disorders of matrix remodeling share a
common paradigm with disease progression: provisional matrices formed in the
context of injury emit signals to promote inflammatory responses and activate
epithelial cells, provoking the production of connective tissue elements that lead to
persistent and at times permanent matrix remodeling [190]. These changes in the
rate of tissue remodeling likely plays an important role in pulmonary disease
progression.
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Increased collagen deposition in IPF is associated with marked increases
in lung stiffness, which has been shown to alter fibroblast morphology,
proliferation, TGF-b signaling, and myofibroblast activation [59, 191-194]. Collagen
fibers affect matrix stiffness by strengthening protein–protein interactions and
other physical characteristics such as resistance to proteolysis, emergence of
neoepitopes, and enhanced cell–matrix interactions [195]. Collagen crosslinking
can also play a major role in determining matrix stiffness, which feedbacks to
increase additional collagen deposition in fibroblasts [196]. Enzymes can affect
crosslinking, such as the lysyl oxidase family [195]. These various posttranslational modifications can result in significant changes of ECM moduli (protein
ratios) and resultant pathology when normal remodeling functions are modified.
Traditionally, in vitro studies of cell-matrix interactions have used matrixcoated culture dishes of either solidary proteins such as collagen, or mixtures like
MatrigelÒ. These conditions do not recapitulate the in vivo 3D environment,
however, as they lack characteristics such as the heterogeneity of lung tissue or
3D orientation of proteins. In vivo, cells protrude in all directions, often coming into
contact with several ECM proteins at once. This is a limitation of culture systems,
where cells react differently than cells in 3D environments [197-200]. Additionally,
in vivo, cells are exposed to different ECM stress and strain forces due to the lung
continuously expanding and contracting, exposing pulmonary cells (endothelial,
epithelial and fibroblasts) to rhythmic stress and strain, which are necessary for
cellular homeostasis. For example, airway epithelium exposed to cyclic stretching
increases the production of surfactant and barrier function [201].
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To study these 3D microenvironments in a more relevant system, the
process of organ decellularization was developed, removing all cellular material,
while retaining the ECM in its native 3D structure. Several processes have been
published with variability in loss of proteins, growth factors, and matrix-associated
molecules, depending on detergents uses, pressure applied, and the length of the
process [202-204]. Decellularization allows measurement of the mechanical
characteristics of the ECM with the development of physical tools such as the
atomic force microscope (AFM) [205]. AFM is a high-resolution microscopy that
uses a probe to touch the tissue surface and detect characteristics (force, imaging,
sample manipulation) in the nanometer range (Figure 8) [206]. These strain/stress
forces are expressed as elastic (Young’s) modulus, which describes the force
necessary to deform materials [207]. Different organs and tissues have different
Young’s modulus (Pa) based of cell types and composition of ECM, among other
factors, ranging from 50 Pa (blood plasma) to bone (100,000 Pa) (Figure 9) [208].
This is very different from tissue culture dishes which have Young’s moduli of 24GPa [208]. Booth et. al. showed that after removal of cells, the normal human
lung elastic modulus is 0.44 to 7.5 kPa [59]. Several pulmonary diseases are
associated with changes in lung Young’s modulus, including emphysema having
decreased stiffness, and fibrotic disorders such as IPF, having increased lung
stiffness [59, 209, 210].
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1.16 Summary
Affecting over 100,000 Americans and carrying a dismal diagnosis, IPF is a
horrible disease. Diagnostic techniques have improved, but understanding the
cause of IPF is still convoluted. This dissertation investigates the potential role of
a transition matrix induced by nicotine exposure, and its effect on IPF formation
and death associated with exposure to lung injury. Additionally, tracking of IPF is
crucial to patient treatment, to which I investigate inclusion of obstructive airway
measurement to improve IPF progression using spirometry values. Improving our
understanding of the mechanisms by which tobacco promotes lung remodeling,
will lead to the development of better tools for diagnostic tracking, care and
treatment of these patients with this horrible condition.
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Figure 8. Mechanisms of Atomic Force Microscopy
Copyright Permissions not required for this type of use. (Bhattacharjee, J. Atomic Force Microscope: Fundamental
Principles) http://www.slideshare.net/joybiitk/atomic-force-microscope-fundamental-principles
(Wikipedia) https://en.wikipedia.org/wiki/Atomic-force_microscopy

Atomic force microscopy is a high-resolution microscope that uses a probe to touch
the tissue surface and detect characteristics (force, imaging, sample manipulation)
in the nanometer range using laser defection off a cantilever. These strain/stress
forces are expressed as elastic (Young’s) modulus, which describes the force
necessary to deform a material.
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Figure 9. Lung Mechanobiology
Reprinted with permission from Nature Publishing Company. [Nature Review Cancer] (Butcher, D.T. et Al., A tense
situation: forcing tumour progression, 2009. 9(2): p. 108-122) Copyright 2009

Substrate stiffness has been shown to alter fibroblast morphology, proliferation,
TGF-b signaling, and differentiation. Organs and tissues have different Young’s
modulus (Pa) based of cells types, composition of ECM, among others ranging
from 50 Pa (blood plasma) to bone (100,000 Pa). This is very different from tissue
culture dishes which have Young’s moduli of 2-4GPa.
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CHAPTER III

MATERIAL AND METHODS

2.1 - Overview

This dissertation consists of in vivo and in vitro experiments capable of
investigating the complex interplay of nicotine and fibroblasts with the extracellular
matrix. My experimental designs shed light on the potential role of nicotine and the
a7 nAChR in the pathogenesis of pulmonary fibrosis.

2.2 - Reagents

The mitogen-enhanced kinase-1 (MEK-1) inhibitor PD98059 was purchased
from New England Biolabs, Inc. (Beverly, MA) and the a7 antagonist, MG-264, was
purchased from Santa Cruz (Dallas, TX). Trypsin 10x was purchased from Corning
Cellgro (Manassas, VA) and diluted to 2.5X with dH20. Mouse a7 nAChR siRNA,
and control non-target siRNAs and Real-Time Quantitative PCR primers (QuantiTect
Primer Assays, Qiagen, Valencia, CA) used to quantify mRNA levels by Real-Time
RT-PCR were purchased from Qiagen.
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All other reagents were purchased from Sigma Chemical Company (St. Louis, MO)
or Fisher Scientific (Pittsburgh, PA) unless otherwise specified.

2.3 - Cell Culture

Murine NIH3T3 fibroblast from the American-Type Culture Collection (CRL
#1658; Manassas, VA) and primary lung fibroblasts (between 3-10 passages) were
harvested from wildtype control C57BL/6 or a7 nAChR deficient C57BL/6 mice
(Jackson Laboratories, Bay Harbor, MA) and cultured in Dulbecco's Modified
Eagle Medium (DMEM; Corning Cellgro), as previously described [77, 211]. The
lack of a7 nAChRs in knock-out mice was verified by RT-PCR and Western Blot
(Figure 12). U937, human monocytic cells permanently transfected with human IL1b gene promoter connected to a luciferase reporter gene were cultured in
400ug/ml HyClone geneticin G418 (Thermo Scientific, Waltham, MA) in RPMI1640 (Corning Cellgro). THP-1 monocytic cells transiently transfected with the
luciferase gene connected to matrix metallopeptidase 9 (MMP-9) promoter were
cultured in RPMI-1640 [212]. All media was supplemented with 10% fetal bovine
serum (Atlanta Biologicals, Lawrenceburg, GA) and 1% Antibiotic Antimitotic
Solution (Corning Cellgro). Cells were grown in Heracell 150 incubators (Thermo
Scientific) at 37°C and 5% CO2. Cell viability was determined by Trypan Blue
exclusion.
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2.4 - Isolation and Detection of mRNAs by Reverse-Transcriptase
Polymerase Chain Reaction

RNA isolation and real-time PCR were performed in two ways. First was
cells were lifted from wells with cell scrapers (Corning) and centrifuged (550 x g
for 5 minutes). PBS were aspirated then 400-500 µL of RNAzol B™ (Tel-test Inc.,
Friendswood, TX) was added to the harvested cells and vortexed. Chloroformisoamyl alcohol (400 µL) was added, vortexed, and placed on ice for 15 minutes.
Samples were spun at 4oC for 15 minutes at 17,500 x g. mRNA was transferred to
a new microfuge tube and 500 µL cold isopropanol were added, mixed, and
incubated on ice for 15-30 minutes. Samples were spun at 4oC for 15 minutes at
17,500 x g, and pellet washed with 95% EtOH and then 70% EtOH. mRNA pellets
were resuspended in 100 µL of RNAse free H2O with 1 mM EDTA. mRNA
concentrations were determined by OD260 x dilution factor x 40 = ng/µl in crystal
cuvettes using a GS-800 Calibrated Densitometer (Bio-rad). Reverse transcription
was performed using iScriptÔ cDNA Synthesis Kit (Bio-rad) according to
manufacturer’s protocol.
PCR was performed using iTaqÔ Universal SYBRâ Green Supermix (Biorad) [211]. Primer sequences are as follows: Mouse collagen type I forward (5’GTGCTGTTGGTGCTGCTG), reverse (5’-CAGGAGCACCAGCAATAC); 18S
forward

(5’-GTGACCAGAGCGAAAGCA),

ACCCACGGAATCGAGAAA);

Mouse

fibronectin

reverse
forward

(5’primer

(CTGTGACAACTGCCGTAG), reverse primer (CAGCTTCTCCAAGCATCG),
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probe

(ACCAAGGTCAATCCACA

C);

IL-1b forward

(5’-

GAGCACCTTCTTTTCC), reverse (5’-CTGGTGGAAGAAAAGG), probe; mouse
a-SMA

forward

primer

(7ATGGAGTCAGCGGGCATC),

reverse

primer

(AACTGGAGGCGCTGATCC), probe (AGCCACCGATCCAGACAG); mouse βactin forward primer (ATGGATGACGATATCGCT), reverse primer (ATGAGGT
AGTCTGTCAGGT), probe (GGATGGCTACGTACATGGCT); and a7 nAChR
forward

(5’-CTGCTGGGAAATCCTAGGCACACTTGAG

GACAAGACCGGCTTCCATCC),

reverse

or
(5’-

CCTGGTCCTGCTGTGTTAAACTGCTTC) in a Labnet Multigene Gradient
thermocycler (Edison, NJ) for PCR and Cepheid SmartCycler (Cepheid,
Sunnydale, CA) for real-time PCR. Negative controls consisted of dH2O and
mRNA without PCR agents. Values were normalized to 18S or GAPDH and
expressed as relative change vs. untreated mouse lung tissue.
The second method of isolation and detection isolated mRNA with QuickmRNAÔ Micro- or Mini-Prep kits (Zymo Research, Irvine, CA) according to
manufacturer’s protocol. Real-time PCR conducted using Fast SYBR Master Mix
(Applied Biosystems, Foster City, CA) using certified mouse primers for 18S
(Mm03928990_g1), b-Actin (Mm04394036_g1), GAPDH (Mm99999915_g1),
Collagen Type 1 (Mm00801366_g1), Fibronectin (Mm01256744_m1), IL1b (Mm00434228_m1) SOD1 (Mm01344233_g1), TGF-b1 (Mm01178820_m1),
TNF-a (Mm00443258_m1) (Life Technologies, Carlsbad, CA) in a StepOnePlusÔ
real-time PCR system (Life Technologies). Negative controls consisted of dH2O
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and mRNA without PCR agents. Values were normalized to 18S, b-Actin, or
GAPDH and expressed as relative change vs. untreated samples.

2.5 - Protein Detection via Western Blotting

Western blots were performed as previously described [77, 211]. Samples
were isolated using western homogenization buffer (50 mM NaCl, 50 mM NaF, 50
mM NaP2O7-10 H2O, 5 mM EDTA, 5 mM EGTA, 2 mM Na3VO4, 0.5 mM PMSF,
0.01% Triton X-100, 10 µg/ml leupeptin, 10 mM HEPES, pH 7.4), and sonicated
for 5 seconds using Sonifier 450 (Branson, Danbury, CT). Protein concentrations
were determined using Bradford reagent (Sigma) readings in DU-800
Spectrophotometer (Beckman Coulter, Brea, CA). Gels were either 10%
(denaturing) or 8% (native) acrylamide gels (Bio-rad, Hercules, CA) run in a mini
trans-blot system (Bio-rad). Samples were heated to 95oC for 5 minutes and spun
for 10 minutes at 17,500 x g. Gels were run for 2 hours at 125 volts using a
Powerpack HC power supply (Bio-rad).
Protein was transferred to Protran Nitrocellulose transfer membrane
(Whatman), between 4 pieces of extra thick western blotting filter paper (Thermo
Scientific), soaked in Pierce Western Blot Transfer Buffer (Thermo Scientific), then
transferred for 2 hours at 25 volts in Trans-Blot SD semi-dry transfer cell (Bio-rad).
Membranes were agitated in wash buffer (3 x 10 minutes) and then incubated in
5% Bovine Serum Albumin or 5% non-dry fat milk blocking buffer for 1 hour. Blots
were incubated with primary polyclonal antibody against either GAPDH (Sigma;
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1:1000 dilution), Collagen type I (Abcam, Cambridge, MA; 1:10000; native, nonreducing gel), p-Smad3 (Rockland Immunochemicals, Gilbertsville, PA; 1:2000),
p-Erk 1&2 (Cell Signaling, Beverly, MA; 1:1000), total Smad3 (Upstate Cell
Signaling, Lake Placid, NY; 1:1000), total Erk (Cell Signaling; 1:1000), and a7
nAChR (Sigma; 1:500) overnight at 4oC. Membranes were agitated in wash buffer
(3 x 10 minutes) before incubation in 2o antibody goat anti-rabbit IgG (Sigma;
1:20,000) for 1 hour at room temperature.
Non-florescent blots were incubated with Amersham ECL Western Blotting
Detection Reagents (GE Healthcare, Little Chalfont, UK) for 5 minutes and
exposed to Genemate Blue Basic Autorad film (Bioexpress, Kaysville, UT) for up
to 1 hour. Protein densitometry was completed using GS-800 Calibrated
Densitometer (Bio-rad).
Florescent lots were incubated with secondary goat anti-rabbit IgG (HRPconjugated) (Li-CORE, Lincoln, NE) (1:20000). Membranes were agitated in wash
buffer (3 x 10 minutes). Florescent blots read on a LI-COR Odyssey CLx imaging
system and analyzed in Image Studio (LI-COR).

2.6 - Cell Viability (Proliferation) Assay

Wildtype or transfected primary lung fibroblasts (1 x 104 cells/ml) were
added to 96-well tissue culture plates and incubated at 37oC for 24 hours in
COMPLETE™ Serum-Free/Low-Protein Medium (Corning Cellgro), then for up to
72 hours with nicotine (50 µg/ml) in the presence or absence of the MEK1 inhibitor,
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PD98059 (50 µM). Afterwards, the luminescence of viable cells was detected using
Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega) in a Luminoskan
Ascent Luminometer (Beckman Coulter) according to the manufacturer’s
instructions.

2.7 - Matrix Deposition and IL-1b Measurement

Fibroblasts were cultured for 24 hours then treated with nicotine (50 μg/ml),
PD98059 (50 µM), and/or MG-264 (10 µM) in DMEM (Cellgro) and retained in
culture in 6 well Costar Cell Culture plates (Corning) for 120 hours. Afterwards, the
fibroblasts were eliminated by osmotic lysis and the remaining matrix-coated
dishes were washed thoroughly [213]. Cells were washed once with PBS
containing 1 mM EDTA (Solution A), then treated for 30 minutes at 4°C with the
solution B (0.25 M NH4OH, 1 mM EDTA, 1 mM PMSF). The cells were washed 2
additional times with solution 3A, and then treated for 15 minutes at 4°C with
solution C (1 M NaCl in 50 mM Tris (pH 7.4), 1 mM EDTA, 1 mM PMSF). Lastly,
the culture plates were washed once with solution A. Isolated matrices were stored
at 4°C with PBS.
Human monocytic U937 cells permanently transfected with the human IL1b gene promoter fused to a luciferase reporter gene were incubated in RPMI1640 on matrix-coated plates for 24 hours [214]. Inhibition was achieved by pretreatment of mouse IgG (1:100, Sigma) or anti-a2b1 integrin (1:100, Abcam)
antibody for 1 hour followed by culturing with the matrix-coated plates 24 hours.
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Afterwards, the luminescence of viable cells was detected using Cell Titer-Glo
Luminescent Cell Viability Assay Kit (Promega).

2.8 - Superoxide Dismutase Activity Assay

Activity of superoxide dismutases was determined using an in vitro assay
as previously published [215]. The quantity of SOD required to produce 50%
inhibition of the rate of reduction of cytochrome c under specified conditions is
defined as 1 unit. Samples were collected in 600 µL cold PPS solution (50 mM
potassium phosphate, 0.1 mM EDTA, H20, pH 7.8) and homogenized thoroughly
and spun for 30 minutes at 14,000 x g. In a GS-800 Beckman Coulter
spectrometer, the control reaction was determined adding Ferricytochrome C
(Cytochrome C) 0.1mM (Sigma #C7752), Xanthine (Sigma #X4002), and
Phosphate buffer (800 µL) into 1 mL plastic cuvette with light path 1 cm at 25°C.
Reaction initiated by adding 10 µL Xanthine Oxidase (Sigma #X4875) and the
sample and read at 550 nm every 30 seconds for 300 Seconds.

2.9 – Murine Housing

Wildtype or a7 nAChR deficient C57BL/6 mice (female, 8-12 weeks;
Jackson Laboratories) were housed on a 12-hour light cycle in a pathogen-free
barrier facility accredited by the Association for Assessment and Accreditation of
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Laboratory Animal Care. The University of Louisville’s Institutional Animal Care
and Use Committee approved all animal studies.

2.10 – Murine Nicotine Exposure

Wildtype and a7 nAChR knockout C57BL/6 mice (female, 8-12 weeks) were
fed a normal diet and exposed to nicotine in their drinking water (100 µg/ml) for 8
weeks as previously described by Rowell et al. [216, 217]. Per Rowell’s research,
mice received an average of 28.6 mg/kg of nicotine a day with a plasma nicotine
concentration approximately 40 ng/ml (0.21 µM), which is comparable to what has
been seen in humans. In vitro doses of nicotine (1-100 µg/ml) used was chosen
based on previous experiments in the lab and published literature [77].

2.11 – Murine Cigarette Smoke Exposure

In collaboration with Douglas Arenberg at the University of Michigan, mice
were exposed to cigarette smoke with an automated smoking machine (JaegerBaumgartner CSM) as previously described [218-220]. The machine draws a puff
of smoke in two seconds at a flow of 1.02 liters/min, once each minute. The smoke
was diluted with medial grade air at 3 liters/min and injected into a sealed 22-gallon
fish tank containing up to 5 Mico-isolator mouse cages (tops removed). This
mixture yields a particulate content of 250 mg/cubic meter. Mice were exposed 4
hours/day 5 days/week for up to 6 months. Exposures are well tolerated using this

40

system for up to one year with acceptable levels of carboxyhemoglobin.

2.12 – Murine Bleomycin-Induced Injury

Bleomycin-induced lung injury was performed as previously described [70].
Mice received either bleomycin (1.0 or 2.0 U/kg) (Sigma) in phosphate-buffered
saline (PBS) or vehicle (PBS) alone intratracheally. Mice were euthanized at 12 or
21 days following injury. Mice were euthanized followed by mRNA and protein
isolation along with en bloc isolation of the lungs for analysis.

2.13 – Murine Bronchoalveolar Lavage (BAL)

Bronchoalveolar lavage (BAL) was performed as previously described
[212]. Cells obtained from BAL were plated for 1 hour at 37°C and the supernatant
collected. Supernatant (100 µL) was cultured on NIH3T3 fibroblasts or THP-1
monocytes for 24 hours. The supernatants from culture were utilized in fibronectin
or MMP-9 gene transcription assays using Luciferase Assay Reagent (Promega)
as previously described [212].

2.14 – Murine Histological Analysis

Mice were euthanized by exsanguination followed by en bloc isolation of the
lungs which were inflated at standard pressure, fixed in formalin, paraffin-
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embedded, and sectioned (5 µm) using JUNG RM2055 microtome (Leica, Buffalo
Groce, IL), then transferred onto Colorfrost microslides (VWR Sciences, Radnor,
PA) for histological analysis. Lung sections were stained using Weigert's iron
hematoxylin for 10 minutes, rinsed in dH20, then treated with Biebrich scarlet-acid
fuchsin solution for 10 minutes. The slides were washed in dH20, then transferred
to aniline blue stain for 30-60 minutes (Masson Tri-chrome Staining Kit, RichardAllan Scientific, Kalamazoo, MI). For Sirius Red/Fast Green staining, slides were
treated with 5% Sirius Red (Polysciences Inc, Warrington, PA) and then were Fast
Green (Achros, New Jersey) saturated with picric acid for 30 minutes each. Lung
microscopy pictures were taken with XL Core EVOS microscope (Life
Technologies, Carlsbad, CA). The tri-chrome slides were blindly graded on their
intensity of collagen staining by 6 investigators based on the Ashcroft score as
previously described [221].

2.15 - Protein Detection via Immunohistochemistry

Immunohistochemistry was performed as previously described [77, 222].
Application of primary antibodies against fibronectin, DAPI, IgG, or IL-1b (Abcam,
1:100 dilution) were incubated at 4 °C overnight. HRP-conjugated secondary
antibodies were applied (Sigma), and the specific staining was visualized with
Vectastain ABC Kit (Vector Labs, Burlingame, CA). Lungs of smoked and nicotinetreated mine were processed and incubated with fibronectin antibodies Afterwards,
the tissue sections were de-identified and the sections were scored for fibronectin
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expression by two investigators blinded to treatment groups.

2.16 – Murine Lung Decellularization

Based off previously published method [59], mice were euthanized by CO2.
Lung and heart were isolated en bloc. All reagents were made fresh for each use.
Lungs were perfused in a 50 mm cell culture dish by injecting 10 cc of DI solution
(dH20 with 1% Antibiotic Antimitotic Solution (Corning Cellgro)) into the right
ventricle of the heart. Three-cc syringe with 19-gauge needle were filled with DI
solution and inserted into trachea and secured with 2 silk suture knots. Lungs were
inflated with DI solution with needle left in trachea. All perfusion steps were
performed by injecting 3 mL intracardiac and intratracheal samples of each of the
solutions and the lungs were allowed to recoil and expel any excess fluid.
Perfusions consisted of 0.1% Trition X-100 (Sigma), 2% Na deoxycholate (Fisher),
1M NaCl (Fisher), and DNAse solution (DNAse I (Sigma), 30 µg/ml in 1.3 mM
MgSO4 and 2 mM CaCl). Perfusions of each solution were followed by incubations
at 4oC on a rocker with gentle stirring for minimum of 1 hour each, and solution
change were performed in the tissue culture hood. After each incubation, the lungs
were flushed with DI solution before the next perfusion. Once the decellularization
process was complete, the lungs were stored in 50 mL conicals containing PBS
with 100 µg/ml Antibiotic Antimitotic Solution (Corning Cellgro) and 2.5 µg/ml
Amphotericin B (Lonza) until embedding.
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Lungs are embedded in 6% Seaprep Ultra Low Agarose (LONZA). Agarose
was prepared on hot plate with stir rod and allowed to mix at medium heat until
fully dissolved. Once melted, agarose was placed in a 55 °C degree water bath
until use. Lung was dried on paper towel and dabbed dry. One and half mL 6%
ultra-low melt agarose was injected into the trachea and heart and the organs were
cut out and the lung dissected into separated lobes, placed into embedding molds,
and covered with additional agarose. The embedded tissue was stored in a sealed
container with a humidification agent.
Lung sections cut on Vibratome (Leica VT 1200, Wetzlar, Germany) at 0.2
mm/s and 500 nm. Loctite (Office Max, Cat# A11363588) was used to glue sample
to cutting platform. Cut samples were stored in DI solution in 50 mL conical. The
agarose was melted by adding the tubes into a water bath set to 50˚C. To sterilize
the slices before use, the DI solution was changed to MQ water plus 0.18%
peracetic acid (Pfalz & Bauer) plus 4.8% EtOH over night or the weekend at 4˚C.
Afterwards, the sterilizing solution was decanted and cold sterile filtered water was
added and rocked in cold room.

2.17 - Atomic Force Microscopy

Matrix stiffness was measured by atomic force microscopy (AFM). Stress is
the magnitude and direction of the force on the cell and strain is the magnitude
and direction of distortion (force/area) [223]. AFM is a very high-resolution type of
scanning probe microscopy that utilizes a cantilever as a probe to characterize the
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surface of a sample. When the tip of the cantilever contacts the sample, forces
between the tip and the sample lead to a deflection of the cantilever. The deflection
is measured based on the displacement of a laser using an array of photodiodes.
Based on a previously published method [165]. Samples were tested with
MFP-3D-Bio AFM Microscope (Asylum Research, Santa Barbra, CA) using
cantilevers with a 0.03 N/m spring and 10 µm SiO2 Sphere tip (Novascan, Ames,
IA). A force map (80 µM scan size) was generated with a 16 x 16 spot test pattern
for a total of 256 points. Each force plot was conducted with a velocity of 2 µM/s
and a trigger point of 500 nM. Young’s modulus was determined using a Hertz fit
model, setting the tip poisson of 0.19 and modulus of 68 GPa, and a sample
poisson of 0.4. The upper limit of the calculation region was set at 75% of the
curve. Data gathered and analyzed using Asylum Modified (Version 14) Igor Pro
software (6.22A WaveMetrics Inc., Portland, OR).

2.18 - Statistical Evaluation

All experiments were repeated using at least 3 samples. Means plus
standard deviations of the means were calculated for all experimental values.
Significance was assessed by p-values <0.05, which were obtained using twotailed t-tests in Microsoft Excel (Redman, WA) or 2-way ANOVA with Bonferroni
posttest in Graphpad Prism 6 (Graphpad Software, La Jolla, CA).

2.19 - PANTHER Trial Data
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The datasets for the Prednisone, Azathioprine, N-acetyl cysteine in IPF
(PANTHER) Trial were obtained from NIH-NHLBI-sponsored Biologic Specimen
and Data Repository Information Coordinating Center (BioLincc). This study was
designed and conducted by the Idiopathic Pulmonary Fibrosis Clinical Research
Network (IPFnet). The trial lasted 60 weeks and participants received a
combination of prednisone, azathioprine, and NAC (combination therapy), NAC
alone, or placebo in a 1:1:1 ratio [224] (ClinicalTrials.gov number, NCT00650091).
At the end of the trial, increased risks of death and hospitalization were observed
in patients treated with a combination of prednisone, azathioprine, and NAC, but
no difference in FVC was detected. The database provided 240 patients for
analysis. Because no difference in FVC was detected between treatment and
placebo groups in the trial, all 85 patients (43 placebo/42 treatment) who achieved
>10% decline in the FVC during the study were included in statistical analysis.
Spirometry values were collected every 15 weeks during the trial period of 60
weeks. Secondary outcomes include the frequency of re-hospitalizations and time
of death.

2.20 - PANTHER Trial Statistical Analysis

The analysis was completed in R (Version 3.2.4) [225]. A 10% loss in either
FVC or FEV1/dFVC determined by comparing the baseline to the maximum
reading from the 15, 30, 45, or 60-week follow-up. Descriptive statistics were ran
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comparing placebo and treatment groups. Chi-squared or Fisher’s exact tests were
used as appropriate to test for differences between categorical variables. Wilcoxon
rank sum tests were used to test for differences in continuous variables. The Stuart
Maxwell Marginal Homogeneity Test (an extension of McNemar’s test) was used
to assess differences timing of loss between FVC and FEV1/dFVC. Receiver
operating characteristics (ROC) curves were produced to compare the FEV1/dFVC
ratio versus FVC alone in regards to sensitivity and specificity as a predictor of
death and re-hospitalization.

2.21 - PANTHER Trial Human Subject Protection

This study was approved by the University of Louisville Institutional Review
Board (IRB) – Human Subjects Protection Program Office (HSPPO).
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CHAPTER III

THE EFFECTS OF NICOTINE ON LUNG FIBROBLAST PROLIFERATION AND
COLLAGEN EXPRESSION/DEPOSTION IN VITRO AND IN VIVO, AND THE
CHOLINERGIC RECEPTORS RESPONSIBLE FOR THESE EFFECTS

3.1 Introduction

Tobacco is considered the single greatest cause of preventable death in the
world [226]. Chronic tobacco exposure is associated with the development of
chronic lung disorders like chronic obstructive pulmonary disease and idiopathic
pulmonary fibrosis (IPF), and is the main cause of lung cancer globally [226].
Tobacco smoke contains more than 4000 chemicals, which interact with a
multitude of molecules and pathways, preventing the effective and safe targeting
of a single mechanism of action with significant therapeutic benefit. A larger effect
of tobacco smoke inhalation is the induction of inflammation, a process
characterized by the release of soluble mediators, oxidant stress, and the
recruitment of inflammatory cells into tissue [227]. This promotes tissue
remodeling, including alterations in lung structure and function, and oncogenesis
[228].
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Due to nicotine’s well known addictive effects, attention has turned to this
plant derived alkaloid which represents ~0.6–3.0% of the dry weight of tobacco.
Recent studies have unveiled the effects of nicotine on lung development [34, 35]
and on inflammatory processes [229]. This is possible because of the existence
of nicotinic receptors in lung tissue capable of signal transduction [79]. These
receptors, termed nicotinic acetylcholine receptors (nAChRs), are multimeric
acetylcholine-triggered channel proteins that form homomeric and heteromeric a
and b chain pentameters. The a7 nAChR is the most abundant homomeric
receptor form, composed of five a7 subunits. In developing primate lungs, a7
nAChRs were detected in airway epithelial cells, around large airways and blood
vessels, free alveolar macrophages, alveolar type II cells, and pulmonary
neuroendorcrine cells [34]. Additionally, increased a7 nAChR expression has been
shown with nicotine administration in bronchial epithelial and endothelial cells as
well being implicated in regulation of inflammation and cancer [77, 92-94].
Our laboratory has previously demonstrated that nicotine stimulates lung
fibroblasts to express fibronectin through induction of the MEK-1/Erk pathway [77].
Fibronectin is a matrix glycoprotein, which is highly expressed in injured tissues,
and is considered a sensitive marker of tissue injury and activation of tissue
remodeling [60, 61]. In an injured lung, fibronectin is deposited over denuded
basement membranes where it is thought to support the migration of alveolar
epithelial cells during repair [61]. The excessive deposition of fibronectin, however,
has been hypothesized to promote disrepair [70]. Human studies also show
increased fibronectin content in the bronchoalveolar lavage fluid of smokers [75].
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However, nicotine-induced fibronectin expression and deposition are not sufficient
to alter overall lung architecture and to date there are no data suggesting that
nicotine, alone, promotes significant lung tissue remodeling.
In this study, nicotine is shown to stimulate lung fibroblasts to express
collagen type I. This fibrillar collagen is another extracellular matrix component
highly expressed in tissues during injury and repair, and its expression signals
activation of tissue remodeling. Collagen type I is the most abundant form of
collagen in the human body and is present in connective tissue throughout the
body including tendon, ligament, skin, and lung tissue. Each rope-like procollagen
molecule is made up of three chains: two pro-a1 (I) chains, which are produced
from the COL1A1 gene, and one pro-a2 (I) chain, which are produced from the
COL1A2 gene. After processing, the resulting mature collagen molecules arrange
themselves into long, thin fibrils. Individual collagen molecules are then crosslinked to one another within these fibrils thereby forming strong collagen fibrils.
Studies performed in vivo confirmed nicotine induction of collagen type I without
changes in overall lung architecture in lung matrix. Also, we found that nicotinetreated fibroblasts produce a collagen-containing matrix capable of stimulating
monocytic cells to produce the pro-inflammatory cytokine IL-1b in vitro.
Together, these observations suggest that nicotine stimulates alterations in
the relative composition of the lung extracellular matrix favoring fibronectin [77]
and collagen type I (this report) expression without altering the overall tissue
architecture of the lung. These subtle changes may render the host susceptible to
excessive tissue damage after injury.
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3.2 Results

Nicotine stimulates the expression of collagen type I
While exploring the effects of nicotine on lung cells, we found that nicotine
stimulated the expression of collagen type I in lung fibroblasts. As depicted in
Figure 10, nicotine induced the expression of collagen type I mRNA in a dosedependent fashion (Figure 10). Maximum mRNA expression was observed at 50
μg/ml of nicotine. Twenty-four hours after nicotine stimulation, increased collagen
type I protein was detected in cell extracts (Figure 10). Nicotine also stimulated
collagen type I mRNA and protein expression up to 72 h (Figure 11).

Role of a7 nAChRs in collagen expression and cellular proliferation
We evaluated the expression of a7 nAChR in a7KO and wildtype mice
(Figure 12). RT-PCR verified the absence of a7 nAChRs in the a7KO mice. We
then evaluated nicotine-induced collagen type I mRNA expression in primary lung
fibroblasts harvested from a7KO animals. Nicotine failed to stimulate collagen type
I expression in a7KO cells (Figure 12). Similarly, we found nicotine did not induced
collagen type I protein expression in a7KO fibroblasts. (Figure 12). Nicotine also
stimulated the proliferation of lung fibroblasts and this effect was also through a7
nAChRs. As depicted in Figure 13, nicotine-induced proliferation was inhibited at
48 and 72 h by siRNA silencing of a7 nAChRs. Additionally, the mitogenic effects
of nicotine were inhibited by PD98059, a MEK-1/ERK inhibitor (Figure 14).
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Figure 10. Nicotine Stimulates Collagen Type I mRNA and Protein
Expression
Vicary et. Al. 2016

(A) Primary lung fibroblasts (1 x 106 cells/6 well) were treated with nicotine (1-75
μg/ml) for 24 hours. Real-time PCR reactions were performed using mouse
collagen type I or 18S primers. Note that nicotine induced a dose-dependent
increase in collagen type I mRNA expression. mRNA levels were normalized to
18S and collagen type I levels compared to untreated controls. (B) Nicotine-treated
fibroblasts were subjected to Western blot analysis using anti-collagen type I
antibody or GAPDH, followed by secondary goat anti-rabbit IgG (IRDyeÒ). Protein
bands were separated by native (collagen type 1) or SDS-PAGE (GAPDH) gel
electrophoresis (8%) and quantified by densitometry. Collagen type I levels were
elevated in the presence of nicotine (50 μg/ml). Significance was assessed using
p values <0.05 obtained by two-tailed t-test.
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Figure 11. Nicotine Stimulates Collagen Type I mRNA and Protein
Expression at 48 and 72 Hours
Vicary et. Al. 2016

(A) Primary lung fibroblasts were treated with nicotine (50 µg/ml) for up to 72
hours. Nicotine induced a significant increase in collagen type I mRNA levels at 48
hours. (B) Fibroblasts were treated with nicotine (50 µg/ml) for up to 72 hours.
Collagen type I protein was increased at 48 and 72 hours by Western blot analysis.
C: Purified rat-tail collagen. All experiments repeated at least 3 times. Significance
was assessed using p values <0.05 obtained by two-tailed t-test.
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Figure 12. Nicotine Induces Collagen Type I Through a7 nAChRs
Vicary et. Al. 2016

(A) The absence of a7 nAChR was verified by mRNA and protein expression in
the a7 nAChR deficient (a7KO) mice. (B) a7KO fibroblasts were exposed to
nicotine for 24 hours. Nicotine failed to stimulate collagen type I mRNA expression
in a7KO cells. (C) Nicotine-treated a7KO fibroblasts were subjected to Western
blot analysis. Nicotine did not stimulate increased collagen deposition in a7KO
fibroblasts. Experiments were repeated at least 3 times. Significance was
assessed using p values <0.05 obtained by two-tailed t-test.
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Figure 13. Nicotine Stimulates the Proliferation of Lung Fibroblasts via a7
nAChRs
Vicary et. Al. 2016

Lung fibroblasts were cultured for up to 72 hours after transfection with control
(Csi) or a7 nAChR siRNAs (a7si). At the appropriate times, the experiment was
halted and live cells counted. Nicotine stimulated cell proliferation at 48 and 72
hours when compared to control cells (*). Absence of the a7 nAChR induced
significant proliferation compared to control cells at 72 hours (#). a7 nAChR
siRNA inhibited the nicotine-induced response when compared to control cells at
48 hours and significantly decreased proliferation at 72 hours (✣). Experiments
were repeated at least 3 times. Significance was assessed using p values <0.05
obtained by 2-way ANOVA with Bonferroni posttest.
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Figure 14. Nicotine Stimulates the Proliferation of Lung Fibroblasts via
Induction of ERK
Vicary et. Al. 2016

Fibroblasts were cultured for up to 72 hours with or without nicotine (50 µg/ml) in
the presence or absence of PD98059 (MI, 50 µM), an inhibitor of MEK-1. Nicotine
stimulated fibroblast proliferation at 48 hours, but the effect was most noticeable
at 72 hours (*). The inhibitor PD98095 alone had a small effect on the proliferation
of cells at 72 hours (#), but did inhibited the stimulatory effect of nicotine (✣).
Experiments were repeated at least 3 times. Significance was assessed using p
values <0.05 obtained by 2-way ANOVA with Bonferroni posttest.
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Nicotine increases collagen expression in vivo
To study the effects of nicotine in vivo, wildtype and a7KO mice were
exposed to nicotine in their drinking water (100 µg/ml) for 12 weeks to test if the
mechanisms described above are relevant to the situation in vivo. This model has
been shown to increase nicotine levels in blood and tissue similar to those of heavy
smokers without affecting body weight [217]. Lower concentrations (<1 µg/ml) of
nicotine can be found in the blood of smokers, while higher concentrations (1-10
µg/ml) are deposited in body tissues [216]. As depicted in Figure 15, the lungs of
mice exposed to nicotine showed increased collagen type I mRNA expression.
a7KO mice showed an insignificant increase in collagen type I mRNA. Protein
analysis showed an increase in collagen type I, p-ERK 1/2, and p-Smad3 protein
expression when compared to control lungs (Figure 16).
Histological analysis was performed on lung tissue harvested from
untreated and nicotine-treated animals and found increased collagen deposition in
wildtype mice treated with nicotine, noticeably around airway and vascular
structures (red arrows) in tissues submitted to both Masson’s tri-chrome and Sirius
red staining (Figure 17). The increase in collagen was confirmed by blinded scoring
of unlabeled tissue slides by eight investigators. Nicotine also failed to stimulate
collagen deposition in the a7KO mice (Figure 18).
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Figure 15. Nicotine Stimulates Collagen Type I mRNA Expression in Lung
through the a7 nAChR In Vivo
Vicary et. Al. 2016

The lungs of wildtype mice exposed to nicotine (100 µg/ml) in the drinking water
for 90 days were isolated for MRNA analysis, which showed an increase in
collagen type I expression (Col (I)) in nicotine-treated wildtype mice, but not in a7
nAChR deficient (a7KO) mice. Experiments were repeated at least 3 times.
Significance was assessed using p values <0.05 obtained by two-tailed t-test.
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Figure 16. Nicotine Stimulates p-Erk, p-Smad3 and Collagen Type I Protein
Expression in Lung through the a7 nAChR In Vivo
Vicary et. Al. 2016

Protein analysis the lungs of wildtype mice exposed to nicotine (100 µg/ml) in the
drinking water for 90 days showed increased p-Smad3, p-Erk 1/2 and collagen
type I (Col(I)) when compared to control lungs. P-Erk, p-Smad3, and collagen type
1 were all completed on the same gel, with the blot stripped between probings.
Total Erk and Smad3 gels were run on a separate gel and stripped between
probings. Experiments were repeated at least 3 times. Significance was assessed
using p values <0.05 obtained by two-tailed t-test.
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Figure 17. Nicotine Stimulates Collagen Expression in Lung In Vivo
Vicary et. Al. 2016

(A) The lungs of wildtype mice exposed to nicotine (100 µg/ml) in the drinking
water for 90 days were inflated at standard pressure, fixed in formalin, paraffinembedded, and sectioned (5 μm) for histological analysis. Lung sections were
stained for tri-chrome or Sirius Red/Fast Green. Arrows indicate increased
collagen type I deposition (blue stain or Red stain) in wildtype animals exposed to
nicotine. (B) The tri-chrome slides were blindly graded on a scale of 0-3 based on
the intensity of collagen staining. Significance was assessed using p values <0.05
obtained by two-tailed t-test.
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Figure 18. Nicotine-Induced Collagen Expression Mediated via a7 nAChRs
in Lung In Vivo
Vicary et. Al. 2016

Lungs of a7KO mice exposed to nicotine (100 µg/ml) in the drinking water for 90
days were inflated at standard pressure, fixed in formalin, paraffin-embedded, and
sectioned (5 µm) for histological analysis. Nicotine treatment resulted in no
differences in tri-chrome staining in a7 nAChR deficient mice.
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Extracellular matrices derived from nicotine-treated lung fibroblasts
stimulate monocytic cell expression of IL-1b
We then investigated whether matrices derived from nicotine-treated
fibroblasts exert a differential effect on immune cells. For this, we cultured U937
human monocytic cells atop of matrices derived from untreated or nicotine-treated
fibroblasts; U937 cells expressed the human IL-1b gene promoter fused to a
luciferase reporter gene [214]. As presented in Figure 19, we found that IL-1â
gene transcription was increased about 2-fold when cultured atop of matrices
derived from nicotine-treated fibroblasts when compared to cells cultured atop
matrices derived from untreated fibroblasts. This effect appeared to be mediated
by collagen binding to a2b1, a collagen integrin receptor, since anti-a2b1
antibodies inhibited the induction of IL-1b (Figure 19). Importantly, IL-1b gene
transcription was not increased in U937 cells cultured atop matrices derived from
nicotine-treated a7KO lung fibroblast (Figure 20). Treatment of fibroblasts with
MEK-1 inhibitor PD98059 or an a7 nAChR inhibitor MG 624 prior to exposure to
nicotine blunted U937 IL-1b induction by the matrix (Figure 21, Figure 22). Lastly,
this process might be relevant in vivo since whole lung MRNA from nicotine-treated
mice

showed

elevated

IL-1b

gene

immunohistochemistry (Figure 23).
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Figure 19. Matrices Derived from Nicotine-Treated Fibroblasts Stimulate IL1b Expression in Monocytic Cells Through the a2b1 Integrin Receptor
Vicary et. Al. 2016

Lung fibroblasts (5x104 cells/12 well) were treated with nicotine (50 µg/ml) for 120
hours. Fibroblasts were removed by osmotic lysis, the plates were washed
thoroughly, and human monocytic U937 cells expressing the human interleukin-1b
gene promoter connected to a luciferase reporter gene were overlaid atop the
fibroblast-derived matrix. Afterwards, expression of the IL-1b promoter was
analyzed by luciferase assay. Collagen-containing matrices derived from nicotinetreated fibroblasts stimulated monocytic cells to express the pro-inflammatory
cytokine IL-1β (*). Furthermore, nicotine-treated fibroblast matrix induction of IL-1b
was significantly decreased by anti-a2b1 integrin antibodies (#). Experiments were
repeated at least 3 times. Significance was assessed using p values <0.05
obtained by 2-way ANOVA with Bonferroni posttest.
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Figure 20. Pro-Inflammatory Matrices Derived from Nicotine-Treated
Fibroblasts Mediated by a7 nAChR
Vicary et. Al. 2016

Wildtype and a7 nAChR deficient lung fibroblasts (a7KO) (5x104 cells/12 well)
were treated with nicotine (50 µg/ml) for 120 hours. Fibroblasts were removed by
osmotic lysis, the plates were washed thoroughly, and human monocytic U937
cells expressing the human interleukin-1b gene promoter connected to a luciferase
reporter gene were overlaid atop the fibroblast-derived matrix. Afterwards,
expression of the IL-1b promoter was analyzed by luciferase assay. IL-1b gene
transcription was not increased in U937 cells cultured on matrices derived from
nicotine-treated a7 nAChR deficient primary lung fibroblast matrix over control.
Experiments were repeated at least 3 times. Significance was assessed using p
values <0.05 obtained by 2-way ANOVA with Bonferroni posttest.
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Figure 21. Pro-Inflammatory Matrices Derived from Nicotine-Treated
Fibroblasts Blocked by a7 nAChR Inhibitor
Vicary et. Al. 2016

Wildtype lung fibroblasts (5x104 cells/12 well) were treated with nicotine (50 µg/ml)
and MG 624, an a7 nAChR antagonist (10 µM), for 120 hours. Fibroblasts were
removed by osmotic lysis, the plates were washed thoroughly, and human
monocytic U937 cells expressing the human interleukin-1b gene promoter
connected to a luciferase reporter gene were overlaid atop the fibroblast-derived
matrix. Afterwards, expression of the IL-1b promoter was analyzed by luciferase
assay. Fibroblasts treated with MG 624 concurrently with nicotine inhibited IL-1b
expression without affecting baseline expression. Experiments were repeated at
least 3 times. Significance was assessed using p values <0.05 obtained by 2-way
ANOVA with Bonferroni posttest.
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Figure 22. Pro-Inflammatory Matrices Derived from Nicotine-Treated
Fibroblasts Blocked by MEK-1 Inhibitor
Vicary et. Al. 2016

Wildtype lung fibroblasts (5x104 cells/12 well) were treated with nicotine (50 µg/ml)
and PD98059, MEK-1 inhibitor (50 µM), for 120 hours. Fibroblasts were removed
by osmotic lysis, the plates were washed thoroughly, and human monocytic U937
cells expressing the human interleukin-1b gene promoter connected to a luciferase
reporter gene were overlaid atop the fibroblast-derived matrix. Afterwards,
expression of the IL-1b promoter was analyzed by luciferase assay. Fibroblasts
treated with PD98059 concurrently with nicotine inhibited IL-1b expression without
affecting baseline expression. Experiments were repeated at least 3 times.
Significance was assessed using p values <0.05 obtained by 2-way ANOVA with
Bonferroni posttest.
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Figure 23. Nicotine Stimulates IL-1b Expression in Lung In Vivo
Vicary et. Al. 2016

(A) The lungs of mice exposed to nicotine (100 µg/ml) in the drinking water for 90
days were isolated for mRNA analysis, which showed an increase in IL-1b gene
transcription by RT-PCR. (B) Lungs from control and nicotine-treated mice were
stained by immunohistochemistry for IL-1b. Increased staining was present in mice
treated with nicotine. Experiments were repeated at least 3 times. Significance was
assessed using p values <0.05 obtained by two-tailed t-test.
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3.3 Discussion

Tobacco-related lung disease is an important health problem worldwide.
Several studies suggest that tobacco exposure promotes lung tissue remodeling
through oxidant stress, inflammation, and the induction of matrix-degrading
proteases, among other mechanisms. The latter is supported by animal studies
showing that overexpression of matrix metalloproteinase (MMP)-1 promotes the
development of emphysema in transgenic mice, while the lack of MMP-12 is
protective [219, 230]. Furthermore, alterations in MMPs and other proteases have
been detected in humans with tobacco-related lung disease [231]. Unfortunately,
this information has not yet translated into the development of effective therapeutic
strategies. Here, we explore another mechanism of action, the induction of lung
tissue remodeling through stimulation of extracellular matrix deposition. We
hypothesized that nicotine, a major component of tobacco, is not only involved in
tobacco addiction, but stimulates lung fibroblasts to release matrix components
that affect the relative composition of the lung matrix. Consistent with this idea, we
found that nicotine stimulates lung fibroblast expression and release of collagen
type I up to 72 hours.
Previously, we reported that nicotine stimulates the expression in lung of
fibronectin, a matrix glycoprotein implicated in injury and repair [77]. However,
fibronectin matrices are often considered 'transitional' matrices whose deposition
does not necessarily lead to irreversible changes in tissue architecture in the
absence of other factors. The discovery that nicotine also stimulates the deposition
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of fibrillar collagens (this dissertation) is important because it suggests that the
effects of nicotine on matrix composition may be more permanent. Collagen type I
is highly expressed in injured lungs as demonstrated in acute lung injury, COPD,
and chronic fibrotic lung disorders [232]. Additionally, collagen has been
associated with extralobar pulmonary artery stiffening caused by chronic hypoxia
[233],

induction

of

epithelial-to-mesenchymal

transition

in

non-small

cell lung cancer cell lines [234], and stimulation of cell chemotaxis by its fragments
[235].
Considering the importance of the proposed mechanisms of action, we
turned our attention to the pathways involved in stimulation of collagen expression.
We found that nicotine affected collagen expression in lung fibroblasts by acting
on a7 nAChRs. Several studies have implicated a7 nAChRs in lung branching
morphogenesis and in the pathogenesis of lung cancer [236, 237]. More recently,
a7 nAChRs were found to mediate the effects of nicotine in developing lungs [35,
238]. Specifically, morphological airway abnormalities and airflow limitation were
detected in the offspring of nicotine-treated wildtype animals, but not in animals
lacking a7 nAChRs. Interestingly, and reminiscent to our work, collagen was found
to be upregulated around the airways of animals exposed to nicotine. Based on
the information presented here and the growing number of publications implicating
a7 nAChRs in multiple disease states, it is reasonable to consider a7 nAChRs as
promising targets for drug development to counteract the deleterious effects of
tobacco. This is now possible considering that the technology to develop safe and
effective agents that target nAChRs are currently available for human use [239].
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Another important finding was that nicotine also stimulated fibroblast
proliferation, a process capable of further promoting tissue remodeling. This effect
was also mediated via a7 nAChRs as demonstrated by the lack of response in
cells silenced for a7 nAChRs. In prior work, we and others demonstrated that
nicotine leads to ERK activation [77]. Consequently, we tested the role of ERK and
found that a MEK-1/ERK inhibitor, PD98059, inhibited nicotine-induced fibroblast
proliferation.
To determine the potential relevance of our in vitro findings, we tested
nicotine exposure in vivo. Previous studies have shown nicotine increases
collagen type I expression in vivo in rhesus monkeys [90]. We exposed mice to
nicotine in their drinking water for 8 weeks. When examined, the harvested lungs
from nicotine-treated wildtype mice showed increased collagen deposition
predominating around airway and vascular structures as determined by
immunohistochemistry. Consistent with our in vitro findings, lung tissue also
showed increased phosphorylation of ERK. We also detected increased
phosphorylation of Smad3, a transcription factor known for mediating many of the
pro-fibrotic effects of transforming growth factor-b. Increased Smad3 has been
associated with collagen expression in cardiac and dermal fibroblasts [240, 241].
Our findings suggest that nicotine is capable of promoting fibronectin [77]
and collagen type I (this report) deposition in lung without affecting the organ’s
overall architecture. We refer to this process, which appears to be self-limiting, as
“transitional remodeling”. Since deposition of new collagen fibrils in our model were
not associated with dramatic alterations in lung architecture, how then do these
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subtle changes in lung matrix composition affect the lung? We reasoned that these
newly deposited collagen fibrils do not affect the lung in the absence of other
injurious stimuli, but instead, may influence immune cell function after injury.
Consistent with this idea, our lab has previously shown that purified collagen type
I can robustly activate monocytic IL-1b expression [242]. In this report, we show
that collagen-containing matrices derived from nicotine-treated fibroblasts are
capable of activating monocytic cells and stimulating their expression of the proinflammatory cytokine IL-1b. This pro-inflammatory event was inhibited by
pretreating fibroblasts with antibodies against a2b1, a collagen-binding integrin
[243], PD98059 (MEK-1 inhibitor), MG 624 (a7 nAChR inhibitor), or matrices
derived from nicotine-treated a7KO primary lung fibroblasts when compared to
control. Increased IL-1b gene expression was also detected in the lungs of
nicotine-treated mice (Figure 23). In addition to monocytic cells, integrins also
control immune responses in T cells. For example, integrin-mediated binding to
collagen provides a co-stimulatory signal for T cell activation [244], resulting in
increased proliferation and secretion of pro-inflammatory cytokines such as TNFa and IFN-g [245]. Thus, by promoting subtle alterations in matrix composition,
nicotine may indirectly stimulate the exaggerated expression of pro-inflammatory
cytokines (e.g., IL-1b) by immune cells recruited to the lung after injury, thereby
helping perpetuate inflammation, a process considered important in the
pathogenesis of tobacco-related lung disorders.
Elements of lung transitional remodeling have also been demonstrated in alcoholexposed rats and mice [211, 246], alcoholic subjects [212], post-lung transplant
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recipients [247], and aging mice [70]. However, the implications of lung transitional
remodeling are unknown. It is presumed that if the stimulating agent is eliminated,
a 'normal' matrix is restored. In contrast, persistence of the transitional matrix may
lead to ineffective repair after injury through the induction of pro-inflammatory
agents directly or via the release of matrix fragments [248]. We and others have
suggested that these changes may explain the increased incidence and mortality
observed for acute lung injury in alcoholics [212, 213], the predisposition to lung
cancer in smokers [92, 249], the development of rejection after lung transplantation
[247], and the worse outcomes observed in elderly patients with pulmonary
disorders [70].
Additionally, it is important that we emphasize the implications of this
research to understanding the potential impact (and safety) of e-cigarettes, an area
that remains relatively unexplored. Consistent with this report, early studies
suggested that e-cigarettes cause similar cell changes as those caused by tobacco
exposure [250]. Considering this, in addition to serious concerns about their ability
to serve as a gateway drug for smoking and current non-smokers, the use of these
agents might pose a serious setback for global health with the use of e-cigarettes
in adolescents, which has doubled yearly [251, 252].
However, until further studies are performed, these statements remain
highly speculative. Booth et al., recently published a technique to isolate acellular
lungs, which could provide the methods to study this interaction in a transitional
matrix lung [59]. Nevertheless, the idea that lung transitional remodeling may
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precede processes such as COPD, acute lung injury and pulmonary fibrosis,
among other disorders, is tantalizing and testable.
In summary, chronic nicotine exposure in mice results in lung matrix
remodeling characterized by increased collagen type I expression/deposition in
lung as well as phosphorylation of ERKs and Smad3. In the absence of injury, this
subtle change in matrix composition does not affect the overall lung architecture,
but may promote exaggerated inflammatory (e.g., induction of IL-1b by immune
cells) and repair (e.g., fibroproliferation) responses after injury. These events
appear to be mediated via a7 nAChRs, which may represent promising targets for
intervention if lung transitional remodeling is proven to be a pre-disease
susceptibility state that precedes (and promotes) lung destruction after injury.
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CHAPTER IV

THE EFFECTS OF CHRONIC NICOTINE EXPOSURE ON INJURY-INDUCED
FIBROSIS

4.1 Introduction

Smoking is considered the most important contributing factor in the
development of fibrosing lung disorders including idiopathic pulmonary fibrosis,
where over half of patients with the disease are smokers or ex-smokers [23, 25].
IPF is characterized by progressive lung tissue remodeling and affects over
100,000 Americans [1].
How smoking contributes to tissue remodeling is unclear and work in this
area has been hampered by the complex nature of tobacco smoke, which contains
over 7,000 compounds [26, 27]. Recently, attention has turned to the potential role
of nicotine, an alkaloid present in tobacco, known for driving the addictiveness of
cigarettes. Nicotine has been shown to affect several biological processes
including cell apoptosis, migration, invasion, angiogenesis, inflammation and
immunity [33]. Additionally, the Roman lab has previously demonstrated that

74

nicotine stimulates the proliferation of primary lung fibroblasts as well as their
production of fibronectin, a matrix glycoprotein implicated in tissue injury and
disrepair [46, 77]. I have also found that nicotine promotes the expression and
deposition in lung of collagen type I, a fibrillar collagen highly expressed in
maladaptive repair (Chapter 3). Thus, it appears that nicotine is not just
responsible for tobacco dependence, but might also contribute to the pathogenesis
of chronic lung disease. However, the exact mechanisms by which nicotine
contributes to the pathophysiology of pulmonary fibrosis is unknown. Thus, we set
out to investigate this in a murine model of lung fibrosis.
Several models have been used to study pulmonary fibrosis, yet none of
these models have accurately reproduced the human condition at this time.
Bleomycin-induced lung fibrosis is the most commonly used model use to
investigate the mechanisms that lead to tissue remodeling after lung injury [160].
Studies performed in the bleomycin model of lung injury have provided some
insight into the role of cigarette smoke. Guinea pigs exposed to cigarette extract
for example, having worse lung fibrosis than the bleomycin treatment alone group
[175]. Similarly, bleomycin-induced alveolar architecture derangement was
enhanced by cigarette smoke in hamsters [173]. In another study, however,
cigarette smoke exposure failed to enhance bleomycin-induced lung fibrosis in
rats, but cigarette smoke exposure was not initiated till post bleomycin instillation
[176]. Thus, there appears to be a role for tobacco exposure in pulmonary fibrosis,
but much remains to be elucidated. To date, no studies have been published on
the role of nicotine in bleomycin-induced lung fibrosis. We hypothesized that
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increased baseline levels of fibronectin and collagen due to nicotine exposure,
creating a transitional matrix, would increase bleomycin-induced lung fibrosis.
Nicotine induced fibronectin and a-SMA expression in pulmonary
fibroblasts and mice. The nicotine induction was ablated in a7 nAChR deficient
fibroblasts and mice. Additionally, nicotine induced ECM production indirectly, with
bronchoalveolar lavage fluid from nicotine-treated mice increasing fibronectin
expression in fibroblasts.
To investigate the role of this transitional matrix in pulmonary fibrosis,
wildtype and a7 deficient mice (a7KO) were treated with nicotine for 90 days, then
instilled with bleomycin and euthanized 21 days later. Mice treated with nicotine
and bleomycin had significantly more fibrosis when compared to bleomycin alone,
but the role of a7 nAChRs in mediating this effect was less clear, with a7KO mice
having increased fibrosis at baseline when compared to wildtype, but nicotine
exposure lowered fibrosis in a7KO mice to wildtype levels. Additionally, I
investigated the mechanobiology effects of nicotine-induced fibrosis on the lung,
but no significant differences in lung stiffness were detected between untreated
and nicotine-treated mice instilled with bleomycin. In conclusion, subtle changes
induced by nicotine may render the host susceptible to excessive tissue damage
after injury.
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4.2 Results

Nicotine stimulates fibronectin and a-SMA expression in vitro and in vivo via
a7 nAChRs
Primary lung fibroblasts from wildtype and a7KO mice were cultured with
nicotine for 24 hours and isolated for protein and mRNA analysis. As depicted in
Figure 24 and Figure 25, nicotine stimulation enhanced fibronectin and a-SMA
expression in wildtype lung fibroblasts, but was absent in a7KO cells. In Vivo,
nicotine stimulated fibronectin and a-SMA expression in the lungs of wildtype mice,
but not in a7KO mice (Figure 26 and Figure 27). Similarly, transgenic mice
expressing the human fibronectin gene fused to a luciferase reporter gene were
exposed to nicotine in their drinking water for up to 90 days. Increased expression
of luciferase (i.e. fibronectin) throughout the lung indicates the induction of
fibronectin deposition in lung is due to increased expression in several resident
lung cell types (Figure 28). Furthermore, the ability of the bronchoalveolar lavage
fluid of nicotine-treated animals to stimulate fibronectin expression was
investigated. As depicted in Figure 29, BAL fluid harvested from nicotine-treated
animals stimulates fibronectin expression in otherwise untreated NIH3T3 lung
fibroblasts. We found that this effect appears specific since the BAL fluid of
nicotine-treated animals did not stimulate THP monocytes to express MMP-9, an
enzyme involved in ECM breakdown and remodeling (Figure 29).
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Figure 24. Nicotine Stimulates Fibronectin Protein Expression Through a7
nAChRs
Vicary et. Al., Unpublished

Fibroblasts were harvested from the lungs of wildtype (WT) and a7 nAChR
deficient mice (a7KO) and cultured in the presence or absence of nicotine (N) (50
µg/ml) for 48 hours and isolated for western blot analysis. Actin was used for
normalization purposes. Results expressed as mean optical density (OD) units.
Nicotine stimulated fibronectin production in wildtype cells, but failed to induce a
significant amount of fibronectin in the a7KO fibroblasts. Experiments were
repeated at least 3 times. Significance was assessed using p values <0.05
obtained by two-tailed t-test.
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Figure 25. Nicotine Stimulates a-Smooth Muscle Actin (a-SMA) mRNA
Expression
Vicary et. Al., Unpublished

Fibroblasts were harvested from the lungs of wildtype mice and cultured in the
presence or absence of nicotine (N) (50 µg/ml) for 48 hours and isolated for mRNA
analysis. Actin was used for normalization purposes. TGF-b1 (TGF) served as a
positive control. Nicotine stimulated a-SMA production in wildtype fibroblasts.
Experiments were repeated at least 3 times. Significance was assessed using p
values <0.05 obtained by two-tailed t-test.
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Figure 26. Nicotine Stimulates mRNA Fibronectin Expression through a7
nAChRs In Vivo
Vicary et. Al., Unpublished

Wildtype (WT) and a7 nAChR deficient (a7KO) mice were exposed to nicotine
(100 µg/ml) in the drinking water for 90 days. Lungs were isolated for mRNA
analysis. b-actin was used for normalization purposes. Nicotine stimulated
fibronectin production in wildtype lungs, but not in a7KO mice. Experiments were
repeated at least 3 times. Significance was assessed using p values <0.05
obtained by two-tailed t-test.
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Figure 27. Nicotine Stimulates a-SMA Protein Expression through a7
nAChRs In Vivo
Vicary et. Al., Unpublished

Transgenic mice expressing the human fibronectin gene fused to a luciferase
reporter gene were exposed to nicotine (100 µg/ml) in the drinking water for 90
days. Lungs were isolated for protein analysis. b-actin was used for normalization
purposes. Results expressed as mean optical density (OD) units. Nicotine
stimulated a-SMA production in wildtype lungs, but not in a7KO mice. Experiments
were repeated at least 3 times. Significance was assessed using p values <0.05
obtained by two-tailed t-test.
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Figure 28. Nicotine Stimulates Fibronectin Expression through a7 nAChRs
In Vivo
Vicary et. Al., Unpublished

Transgenic mice expressing the human fibronectin gene fused to a luciferase
reporter gene were exposed to nicotine (100 µg/ml) in the drinking water for 90
days. Lungs were isolated for histology. Increased expression of luciferase
(connected to fibronectin gene) was detected throughout the lung indicating that
the previously reported induction of fibronectin protein deposition in lung is due to
increased gene expression in several resident lung cell types. Experiments were
repeated at least 3 times.
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Figure 29. Bronchoalveolar Lavage (BAL) Fluid from Nicotine-Treated Mice
Induced Fibronectin Expression in NIH3T3 Fibroblasts
Vicary et. Al., Unpublished

(A) BAL fluid was harvested from wildtype mice exposed to nicotine (100 µg/ml) in
the drinking water for 90 days. BAL fluid was cultured with NIH3T3 fibroblasts
transfected with the human fibronectin promoter connected to a luciferase reporter
gene for 24 hours. BAL fluid from nicotine-treated mice induced significant
expression of fibronectin. (B) BAL fluid did not stimulate the expression of the
MMP-9 promoter in THP-1 cells transfected with a MMP-9 promoter-luciferase
construct. B: baseline; C: BAL fluid from control animals; N: BAL fluid from nicotine
treated animals. Experiments were repeated at least 3 times. Significance was
assessed using p values <0.05 obtained by two-tailed t-test.
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Nicotine enhances bleomycin-induced lung fibrosis through a7 nAChRs
Having examined the effects of nicotine on fibronectin and a-SMA
expression in vitro and in vivo, we turned our attention to its effects on bleomycininduced lung fibrosis. Untreated and nicotine-treated animals were administered
bleomycin (1.0 U/kg) intratracheally to promote the development of fibrosis. As
hypothesized, bleomycin-induced lung fibrosis was increased in nicotine treated
mice as observed by histology (Figure 30). However, the role of a7 nAChRs in
mediating the increased fibrosis seen in nicotine-treated mice is unclear. a7KO
mice treated with bleomycin alone had increased fibrosis at when compared to
wildtype mice treated with bleomycin alone, but was dissipated with nicotinetreatment (Figure 30).

Creation of an ex vivo model and determination of lung stiffness
Lungs from wildtype control and nicotine-treated mice instilled with
bleomycin mice were decellularized by perfusions of DI solution (dH20 with 1%
Antibiotic Antimitotic Solution), 0.1% Trition X-100, 2% Na deoxycholate, 1M
NaCl, and DNAse solution and embedded in 6% Seaprep Ultra Low Agarose
(Figure 31). Acellular lung sections were cut in a vibratome and stained for
hematoxylin, tri-chrome, and immunostaining. Lack of DAPI staining showed
removal of cellular material with ECM remaining in normal architecture (Figure
32).

84

Acellular lungs from bleomycin and bleomycin and nicotine treated mice
were tested for possible mechanical property differences by atomic force
microscopy. A force map of each sample was conducted and stiffness
measurements (pascals) were averaged. There were no significant differences in
lung stiffness between bleomycin and bleomycin and nicotine treated mice due to
the large variation in stiffness within each lung (Figure 33).
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Figure 30. Nicotine Induces Bleomycin-Induced Fibrosis
Vicary et. Al., Unpublished

The lungs of wildtype and a7 nAChR deficient (a7KO) mice exposed to nicotine
(100 µg/ml) in the drinking water for 120 days. Bleomycin was administered
intratracheally at a dose of 1.0 U/kg body weight. Surviving animals were sacrificed
at 21 days post-bleomycin. (A) The lungs were processed and stained by
Masson’s trichrome staining. (B) Slides were blindly graded with PBS control lungs
scored as 1 on the Ashcroft scale. Nicotine caused an increase in bleomycininduced pulmonary fibrosis at 21 days in WT mice. Nicotine’s affects were not
present in a7KO mice, but interestingly, a7KO mice had increased fibrosis with
bleomycin alone when compared to wildtype mice. Experiments were repeated at
least 3 times. Significance was assessed using p values <0.05 obtained by twotailed t-test.
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Figure 31. Lung Decellularization
Vicary et. Al., Unpublished

(A) Lungs were decellularized by perfusing 3 cc of H20 solution into the right
ventricle of the heart and trachea. Perfusions of Triton X-100, deoxycholate, NaCl,
DNase, and peracetic acid followed with incubations in each solution performed at
4oC on a rocker. Acellular lungs are embedded into low temperature SeaPrep™
agarose and cut using a vibratome. (B) Acellular lung sections from control and
bleomycin-treated mice. Bleomycin-treated sections showed increased density of
whiteness (i.e. ECM proteins).
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Figure 32. Verification of Acellular Lung
Vicary et. Al., Unpublished

Acellular and normal lung sections from wildtype mice were stained using
hematoxylin

and

eosin,

Masson’s

tri-chrome,

or

immunohistochemistry.

Immunostaining was carried out with control antibodies and antibodies against
Fibronectin, DAPI, and IgG. Staining showed removal of cellular material with
extracellular matrix proteins in normal architecture remaining.
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Figure 33. Nicotine Did Not Increased Stiffness of Bleomycin-Treated
Lungs
Vicary et. Al., Unpublished

Acellular lungs from bleomycin alone and bleomycin and nicotine treated mice
were tested for stiffness by atomic force microscopy. A force map of each sample
was conducted and stiffness measurements (pascals) were averaged. There were
no significant differences in lung stiffness between bleomycin and bleomycin and
nicotine treated mice due to the large variation in stiffness within each lung.
Experiments were repeated at least 3 times.
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4.3 Discussion

Smoking is considered the most significant contributing factor in several
pulmonary diseases, including IPF, but the mechanisms by which these factors
induce disease need to be elucidated [23, 25]. The pathogenesis of pulmonary
diseases is intriguing with some patients diagnosed with conditions such as IPF
and chronic obstructive pulmonary disease after a relatively brief smoking history,
while others can smoke for years with no detrimental health effects. This could be
due to the requirement of a second hit or multiple chemical exposures to induce
fibrogenesis. Supporting, no studies have shown nicotine alone can induce fibrosis
or any other remodeling disease.
Here the data suggesting that nicotine creates an altered ECM state in the
lung that accelerating fibrosis caused by a second challenge. Nicotine induces a
transitional matrix marked by increased fibronectin, collagen type I, and a-SMA
expression (Figure 17 and Figure 28) [77]. Fibronectin, collagen, and a-SMA are
extracellular matrix proteins implicated in tissue injury and disrepair [46, 77, 253].
This induction of ECM proteins is mediated by a7 nAChRs (Figure 26 and Figure
27). Additionally, immunohistochemistry analysis showed increased expression of
fibronectin throughout the lung, indicating that nicotine is able to induce fibronectin
expression in several resident lung cell types, not just fibroblasts, which are
normally considered the main producer of ECM proteins (Figure 28). Interestingly,
nicotine can also induce fibronectin in an indirect fashion, via BAL fluid (Figure 29).
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Although others and I have shown that nicotine induces ECM proteins, they are at
a subclinical level, not marked by structural changes (Figure 29).
Investigating the role of nicotine-induced transitional matrix in pulmonary
fibrosis induced by injury, mice were exposed to nicotine for 90 prior to bleomycin
instillation. We found nicotine significantly induced bleomycin-induced fibrosis in
wildtype mice (Figure 30). This suggests that the increased collagen and
fibronectin deposition caused by nicotine exposure accelerated fibrosis instigated
by a secondary challenge. The role of a7 nAChRs in mediating this effect is
unclear. Previously, lack of a7 nAChR has been shown to cause increased
fibroblast proliferation and airway hyperplasia in a7 nAChR deficient mice [238,
254]. This may explain the increased fibrosis seen in untreated a7KO mice when
compared to wildtype mice (Figure 30). a7KO mice treated with nicotine ablated
the increased fibrosis, although the mechanism is unclear.
Lastly, we investigated potential changes in the mechanobiology of the lung
caused by nicotine exposure. The lung continuously expanding and contracting,
exposes pulmonary cells to rhythmic stress and strain, which are necessary for
cellular homeostasis [201]. Changes in tissue stiffness have been shown in COPD
and IPF [59, 191-194, 255, 256]. Acellular lungs were isolated from bleomycin
alone and nicotine and bleomycin-treated mice. Removal of cellular material while
maintaining ECM structure was verified by lack of DAPI staining (Figure 32). Using
atomic force microscopy, no differences in lung stiffness were detected between
the two groups (Figure 33). This was due to the large variability in lung stiffness
seen within lungs.
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In conclusion, we present evidence that nicotine induces subtle changes in
lung composition through ECM induction via a7 nAChRs. This increase in proteins
causes significant acceleration of pulmonary fibrosis caused by injury, but the role
of a7 nAChR and lung stiffness are unclear. Clinically, a7 nAChR or ECM
degradation might pose promising targets for the prevention of pulmonary fibrosis
in current and former smokers.
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CHAPTER V

THE IMPACT OF CHRONIC NICOTINE EXPOSURE ON SURVIVAL AFTER
BLEOMYCIN-INDUCED LUNG INJURY

5.1 Introduction

Approximately 40 million Americans smoke cigarettes, costing the U.S.
economy over $175 billion a year in healthcare expenditures [257, 258]. Tobacco
smoke is a risk factor for several pulmonary diseases characterized by tissue
remodeling, including idiopathic pulmonary fibrosis (IPF). Studying how tobacco
smoke promotes these diseases is hindered by tobacco smoke’s complexity,
containing over 7,000 chemicals [26, 27].
Due to the rapid rise of e-cigarettes, research has recently began focusing
on nicotine, the main addictive component in tobacco smoke [259, 260]. Nicotine
interacts with cells via cholinergic receptors capable of signal transduction termed
nicotinic acetylcholine receptors (nAChRs) [35, 238]. These receptors are
multimeric acetylcholine-triggered channel proteins that form homomeric and
heteromeric a and b chain pentameters [261].
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During embryogenesis, nicotine-a7 nAChR interactions influence lung
branching morphogenesis and result in airway thickening and dysfunction [34, 35,
91]. Nicotine has been shown to induce ECM proteins (e.g. collagen type I,
fibronectin, a-SMA), a hallmark of tissue remodeling in lung diseases [47, 77]. This
ECM induction is mediated by a7 nAChRs in lung fibroblasts (Figure 10, Figure
12, and Figure 24) [77]. Nicotine cannot cause clinical remodeling (i.e. fibrosis)
alone, thus, we set out to investigate the effects of chronic nicotine exposure after
a secondary insult using the model of bleomycin-induced lung injury.
Bleomycin instillation generates free radicals injuring DNA [262, 263], lipids
[264], and proteins [265], which drive robust inflammation the first two weeks
closely resembling acute lung injury (ALI) [171, 266, 267].This phase is followed
formation of pulmonary fibrosis during the third week post-instillation [171].
Pulmonary fibrosis has historically been characterized by extensive extracellular
remodeling, but more recent research has connected immune responses [118121]. Activated fibroblasts being highly responsive to additional growth factors/proinflammatory cytokines [118, 119]. This mechanism suggests a capacity for the
immune system to accelerate fibroblast-mediated pulmonary remodeling.
Additionally, oxidants have implicated in pulmonary fibrosis [146].
Superoxide, one of the main oxidants in the lung, has been shown to stimulate
fibroblasts to secrete collagens, a hallmarks of pulmonary fibrosis [268]. To protect
against oxidant damage, the lung has a high abundance of anti-oxidants, including
superoxide dismutases (SODs). Overexpression of superoxide dismutase 3
(SOD3) was protective against fibrosis in the bleomycin model [153]. How tobacco
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(i.e. nicotine) affects anti-oxidants is still being elucidated. Some have postulated
that cigarette smoke promotes the induction of oxidant stress [146]. In rats, nicotine
alone has been shown to affect the oxidative state of the lung by increasing the
activity of superoxide dismutase, an important protective mechanism in lung [151,
152].
We hypothesized that nicotine would augment pulmonary injury in wildtype
bleomycin-treated animals and that this effect would be ablated in a7 nAChR
deficient animals (a7KO). Mice began dying ~12 days post bleomycin instillation,
but surprisingly we found that nicotine was protective against death, and this
protective effect was dependent on the presence of a7 nAChR. Additionally, an
increase in the anti-oxidant SOD1 expression and activity was detected with
nicotine-treated wildtype mice, suggesting a potential mechanism of protection. In
conclusion, our studies suggest that nicotine-a7 nAChR interactions could play an
important role in protection against death caused by bleomycin-induced lung injury.

5.2 Results

Nicotine is protective in high-dose bleomycin–induced lung injury by acting
on a7 nAChRs
To test the role of chronic nicotine exposure in the bleomycin model,
wildtype and a7KO mice were exposed to nicotine (100 µg/ml) in their drinking
water for 90 days followed by intratracheal instillation of bleomycin (2.0 U/kg). This
dose of bleomycin was associated with significant mortality with 80% of animals
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dying within 12 days after bleomycin instillation (Figure 34A). Interestingly, nicotine
exposure was protective with 40% fewer animals dying in response to bleomycin.
Even more interesting was the observation that the protective effects of nicotine
appeared dependent on a7 nAChR expression since animals deficient in this
receptor also experienced high mortality despite nicotine treatment (Figure 34B).
Similar observations were made in animals exposed to nicotine for a longer term
(207 days) (Figure 34C).

Nicotine did not affect bleomycin-induced weight loss or lung fibrosis
We then set out to investigate the mechanisms responsible for the
protective effects of nicotine. First, we examined the body weight of the animals
and found that, as predicted, bleomycin-induced weight loss, but this was not
affected by nicotine exposure or a7 nAChR expression (Figure 35). Second, we
examined the histology of the lungs of the surviving mice. We noted no differences
between the groups, independent of treatment (Figure 36 and Figure 37).

Inflammation does not appear to play a role in the protective role of nicotine
in bleomycin–induced lung injury
Third, we examined the mRNA expression of soluble mediators involved in
inflammation (IL-1b and TNF-a) and fibrosis (TGF-b) in the surviving animals. As
depicted in Figure 38, both nicotine and bleomycin were observed to stimulate the
expression of all three mRNAs, but the expression pattern did not suggest
inflammation as the cause of nicotine-induced protection. Interestingly, lack of a7
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nAChR was associated with increased expression of all three mRNAs at baseline,
but the general pattern of mRNA expression was not greatly affected by nicotine
or bleomycin.

Nicotine induces superoxide dismutase 1 (SOD1) and appears to be
mechanism of the protection in high-dose bleomycin–induced lung injury
Fourth, considering several lines of evidence implicating superoxides as
one of the ROS that mediate lung injury, we examined SOD expression [146].
SOD1 has been shown to mediate asbestosis-induced pulmonary fibrosis through
production of H2O2 [269]. In vitro, we found that nicotine stimulates the expression
of SOD1 in cultured primary lung fibroblasts (Figure 39). Additionally, presented in
Figure 40A and B, nicotine and bleomycin were found to increase SOD1 mRNA
expression in wildtype, but was absent in a7 nAChR KO mice. Lastly, we found
nicotine-treated mice had increased SOD activity when compared to non-nicotinetreated (Figure 41).
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Figure 34. Nicotine Induces Protection Against Dead Caused by BleomycinInduced Lung Injury
Vicary et. Al., Unpublished

(A and B) Wildtype and a7 nAChR deficient (a7KO) mice were exposed to nicotine
(100 µg/ml) in the drinking water for 107 days then instilled with intratracheal
bleomycin (2.0 U/kg). Death occurred in 80% of wildtype mice at 12 days post
instillation. Nicotine induced significant protection in wildtype mice but was absent
in a7KO mice. Wildtype and nicotine-treated mice had 0% mortality, with wildtype
survival line hid behind the nicotine treated mice. (C) Wildtype and a7KO mice
were exposed to nicotine (100 µg/ml) in the drinking water for 207 days then
instilled with intratracheal bleomycin (2.0 U/kg). Death occurred in 80% of wildtype
mice at 12 days post instillation. Nicotine induced protection in wildtype mice but
there was also small amount of protection in a7KO mice.
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Figure 35. Nicotine-Treatment Does Not Affect Bleomycin-Induced Weight
Loss
Vicary et. Al., Unpublished

(A and B) Wildtype and a7 nAChR deficient (a7KO) mice were exposed to nicotine
(100 µg/ml) in the drinking water for (A) 107 or (B) 207 days then instilled with
intratracheal bleomycin (2.0 U/kg). There was no significant difference in weight
lost between the groups tested in A and B. Experiments were repeated at least 3
times. Experiments were repeated at least 3 times. Significance was assessed
using p values <0.05 obtained by 2-way ANOVA with Bonferroni posttest.
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Figure 36. Nicotine-Induced Protection (107 Days) Against BleomycinInduced Death Showed No Differences in Fibrosis
Vicary et. Al., Unpublished

(A) Surviving mice from Figure 34A and B had their lungs inflated at standard
pressure, fixed in formalin, paraffin-embedded, and sectioned for histological
analysis. Lung sections were stained with hematoxylin and eosin. (B) The trichrome slides were blindly graded on the Ashcroft scale. No significance was
found between groups. Experiments were repeated at least 3 times. Significance
was assessed using p values <0.05 obtained by 2-way ANOVA with Bonferroni
posttest.
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Figure 37. Nicotine-Induced Protection (207 Days) Against BleomycinInduced Death Showed No Differences in Fibrosis
Vicary et. Al., Unpublished

(A) Surviving mice from Figure 34C had their lungs inflated at standard pressure,
fixed in formalin, paraffin-embedded, and sectioned for histological analysis. Lung
sections were stained with hematoxylin and eosin. (B) The tri-chrome slides were
blindly graded on the Ashcroft scale. No significance was found between groups.
Experiments were repeated at least 3 times. Significance was assessed using p
values <0.05 obtained by 2-way ANOVA with Bonferroni posttest.
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Figure 38. Nicotine-Induced Protection Against Bleomycin-Induced Death
Not Connected to Inflammation
Vicary et. Al., Unpublished

(A) We examined the mRNA expression of soluble mediators involved in
inflammation (IL-1b and TNF-a) and fibrosis (TGF-b) in the surviving animals. In
wildtype mice, both nicotine and bleomycin stimulated the expression of all three
mRNAs, but the expression pattern did not suggest inflammation as the cause of
nicotine-induced protection. Untreated wildtype controls normalized have
expression equal to 1. (B) Lack of a7 nAChR was associated with increased
expression of all three mRNAs at baseline, and this general pattern of expression
was not greatly affected by nicotine or bleomycin. Untreated a7KO controls
normalized have expression equal to 1. Experiments were repeated at least 3
times. Significance was assessed using p values <0.05 obtained by 2-way ANOVA
with Bonferroni posttest. a = compared to control, b = compared to nicotine, c =
compared to bleomycin
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Figure 39. Nicotine-Induces Superoxide Dismutase 1 (SOD1) mRNA
Expression
Vicary et. Al., Unpublished

Wildtype lung fibroblasts were cultured in nicotine (50 µg/ml) for 24 hours and then
isolated for mRNA. SOD1 expression was significantly upregulated in nicotinetreated fibroblasts. Experiments were repeated at least 3 times. Significance was
assessed using p values <0.05 obtained by two-tailed t-test.
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Figure 40. Nicotine-Induces
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Figure 41. Nicotine-Induces SOD1 Activity In Vivo
Vicary et. Al., Unpublished

In vivo activity of superoxide dismutase was determined using an SOD enzymatic
assay. Nicotine-treated mice significantly increased SOD activity when compared
to control mice. Experiments were repeated at least 3 times. Significance was
assessed using p values <0.05 obtained by two-tailed t-test.
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5.3 Discussion

We set out to investigate the impact of chronic nicotine exposure on
bleomycin-induced lung injury. It is well known that bleomycin-induced tissue injury
is greatly affected by method of injection, timing, and batch of drug. Routes of
injection include inhalational, intratracheal, intraperitoneal, intravenous, and
subcutaneous [270]. During the first two weeks after injection, bleomycin induces
a robust inflammatory response including IL-1b, TNF-a and IL-16 [271]. Bleomycin
also induces an intense oxidant response characterized by increased SOD,
catalase, glutathione peroxidase malondialdehyde [272-277].
Considering reports by us and others showing nicotine induces extracellular
matrix proteins involved in pulmonary fibrosis, we predicted that nicotine would
worsen outcomes [35, 77, 238]. Surprisingly, we found that chronic nicotine
exposure induced protection against death in mice exposed to bleomycin (Figure
34). Perhaps the most important observation we found was that the protective
effect of nicotine was mediated through a7 nAChRs since the mortality of animals
lacking these receptors was the same as that for wildtype animals. Thus, activation
of cholinergic signaling through a7 nAChRs resulted in protection against death in
the setting of bleomycin.
The protective effect of nicotine was early (12 days) after bleomycin
administration suggesting effects during the late inflammatory stage of injury and
not related to the fibrotic process seen later in these animals (Figure 36). Thus, we
speculated that nicotine affect the inflammatory response. Nicotine has been
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shown to have anti-inflammatory effects on macrophages by reducing the
expression of pro-inflammatory cytokines [278-280]. In contrast, we found
increased IL-1b and TNF-a expression in the lungs of nicotine-treated animals,
suggesting nicotine may stimulate inflammatory cytokines in lung (Figure 38). The
cellular origins of these cytokines were not investigated during these studies.
However, the a7 nAChR seems to play a role in mediating an inflammatory
response, with a7KO mice having no or reduced induction of inflammatory
cytokines IL-1b and TNF-a.
Lastly, investigating other potential mechanisms of protection, we found an
increase in SOD1 expression and activity associated with nicotine exposure
(Figure 39 and Figure 40). Previous research supports the protective effects of
anti-oxidants, with overexpression of SOD and inhalation of lecithinized SOD
shown to be protective against bleomycin-induced fibrosis [153, 281]. Additionally,
SOD1 has been shown to attenuate DNA breakage induced by bleomycin in vitro
[282]. Other SODs, such as EC-SOD (SOD 3) are also protective against
bleomycin-induced fibrosis [153]. This mechanism may also be relevant clinically,
since Pirfenidone, an FDA approved drug for pulmonary fibrosis, has been shown
to rescue SOD loss in renal proximal tubular cells [283].
It should be highlighted that we only tested chronic nicotine exposure, which
is likely to elicit responses that differ from those triggered by acute nicotine
exposure. Not much research has been conducted on acute nicotine exposure, but
the lung is a short-term depot for nicotine after exposure, with the lungs showing
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higher levels than the brain [28]. Additionally, acute nicotine exposure raises
cotinine levels similar to chronic exposure, but doesn’t affect lung function [284].
Although these observations point to the involvement of a7 nAChRs and
anti-oxidants mediating the protective effects of nicotine, we were unable to
determine exactly how chronic nicotine exposure protected mice against death
caused by bleomycin-induced lung injury.
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CHAPTER VI

A NEW DIAGNOSTIC PHYSIOLOGICAL FORMULA FOR EARLIER
DECTECTION OF PULMONARY FIBROSIS PROGRESSION IN IPF PATIENTS

6.1 Introduction

Idiopathic pulmonary fibrosis (IPF) is defined progressive bilateral fibrotic
changes of unknown etiology [1, 5]. IPF affects over 100,000 patients in the U.S.
and hundreds of thousands across the world with a dismal survival rate of 3 years
from the time of diagnosis [2, 6, 285]. IPF is difficult to diagnose; characterized by
impaired lung function and presence of usual interstitial pneumonia, often needing
several doctors for confirmation [11, 12, 286]. The number of IPF cases appears
to be increasing; due in part to the aging population, increasing patient and
physician awareness, and improving computer tomography (CT) imaging [10]. In
addition to diagnosis, monitoring IPF severity and progression is critical to
decision-making for treatment, management and timing for lung transplantation.
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Currently two new drugs to treat IPF are on the market, but they are not
curative, only slowing the progression of fibrosis in some individuals [287, 288].
The definitive treatment for IPF is lung transplantation in individuals who qualify
[5]. The progression of fibrosis varies greatly between patients, with some
remaining stable for years, while others decline rapidly [5]. Determination of
disease progression in IPF is multifactorial including reported and objective
measures of exertional tolerance, radiological changes, and measurement of lung
function [289]. Early evidence of pulmonary fibrosis might be manifested by a
decrease in lung capacity and reduced diffusing capacity for carbon monoxide,
which is typical of fibrosing lung disorders. A six-minute walk test (6MWT) with a
portable oximeter should also be considered as hypoxemia may only be detected
during exertion in early stages [5, 290]. Chest imaging is important in confirming
IPF diagnosis with high-resolution computed tomography (HRCT) being the best
imaging for IPF confirmation.
Forced vital capacity (FVC) is the one spirometry measure of lung function
testing that best correlates with disease progression [291, 292]. A 10% decline in
FVC from the baseline measure at diagnosis is considered a significant worsening
and is a major end-point in clinical trials in IPF [50, 51]. The FVC alone, however,
is a surrogate only for the restrictive impairment produced by lung fibrosis and
manifested through increased elastic recoil of the fibrotic tissue compared to
normal lung.
There has been little attention paid to airflow abnormalities in IPF and other
lung fibrosing disorders from a clinical standpoint. In addition to FVC, spirometry
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can also measure airway obstruction by forced expiratory volume in 1 second
(FEV1) [293]. A FEV1/FVC ratio (Tiffeneau-Pinelli index) has been found to
correlate with survival in IPF, but is rarely used clinically [294, 295]. Despite the
lack of attention on airflow changes in IPF, a few studies have suggested that
airflow abnormalities may be a key determinants of survival in this disease [296298]. High lung elastic recoil is believed to make it difficult to blow expiration fast
and consequently makes FEV1/FVC high [299]. Indeed, bronchiolar fibrosis and
inflammation seen in histological specimens of individuals with IPF and other forms
of pulmonary fibrosis have been known for decades and correlate with impairments
in airflow [300-302]. Brown and colleagues found a significantly lower FEV1/FVC
in their 5-year survivor group compared to those who died or received lung
transplants [296]. Additionally, Schwartz et al. found decreased survival in IPF
patients with higher FEV1/FVC [297]. Finally, Wells and co-workers developed a
composite physiologic index for predicting survival in IPF in which the FEV1 is an
important variable [298]. These studies indicate that first, airflow abnormalities are
important in the pathogenesis of IPF and second, that routine clinical tests that
measure both airflow and lung capacities can be used to assess disease severity
and prognosis.
These findings, along with the typical radiological features of traction
bronchiectasis seen in IPF suggest that abnormalities in the airways and airflow
are an important part of the pathogenesis in this disease [12]. Cherniack et. Al.
showed that total lung capacity and FVC correlated the severity and extent of
cellular infiltration of the alveolar walls [303]. Thus, any disease process that
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affects both lung recoil and bronchial structure should impact both airflow and lung
capacity simultaneously. Using the belief that fibrosis causes loss of total lung
capacity and lung elasticity, we focused on the comparison between the standard
FVC measure of disease progression in IPF to a new formula; FEV1/dFVC ratio =
absolute value (FEV1 / (predicted FVC – actual FVC)). The goal of this research
is to detect changes in disease progression and severity earlier in the disease
course, enhancing clinical decision-making and decreasing the time to progression
of end-points in clinical trials (Figure 42).

6.2 Results

Patient Characteristics
The PANTHER trial yielded 264 patients for analysis. Patients were
separated by whether their pulmonary fibrosis progressed over the course of the
study (drop in 10% FVC) (Table 1). Descriptive statistics showed difference in
FVC, FEV1 and DLCO % predicted values. Additionally, CPI and total lung
capacity were different.
The cohort of 85 patients (43 placebo/42 treatment) who achieved >10%
decline in the FVC during the study were selected for FEV1/dFVC analysis (Figure
43). Descriptive statistics compared placebo and treatment groups (Table 2). The
average age of the patients was 67 years with 82% of patient’s being male. Over
74% of the patients are current or former smokers.
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Figure 42. Comparing FEV1/dFVC ratio to FVC Alone
Vicary et. Al., Unpublished

We hypothesize that the FEV1/dFVC ratio will detect IPF progression earlier then
FVC alone. Progression is marked by a decline of 10% from the patient’s baseline
value. Using the belief that fibrosis causes loss of total lung capacity and lung
elasticity, we compare the standard FVC measure of disease progression in IPF
to FEV1/dFVC ratio to detect changes in disease progression and severity earlier
in the disease course, enhancing clinical decision-making and decreasing the time
to progression of end-points in clinical trials.

FEV1/dFVC ratio = absolute value (FEV1 / (predicted FVC – actual FVC))
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Figure 43. PANTHER Trial Enrollment and Outcomes
Vicary et. Al., Unpublished

Patients with IPF between the ages of 35-85 years who had mild- tomoderate lung-function impairment (defined as a forced vital capacity of ≥50% and
a predicted carbon monoxide diffusing capacity of ≥30% were eligible. Patients
had received the diagnosis of IPF on the basis of high-resolution computed
tomography (CT) or biopsy 48 months or less before enrollment. The PANTHER
trial database provided 240 patients for analysis. Individuals who achieved >10%
decline in the FVC during the course of the study were selected for analysis; 42
placebo and 43 treatment patients. No difference was detected in FVC between
the placebo and treatment groups, so all 85 patients were included in statistical
analysis.
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Table 1. Drop in 10% FVC Patient Cohort Baseline Characteristics
Vicary et. Al., Unpublished

The PANTHER trial patients were separated by whether their idiopathic pulmonary
fibrosis (IPF) progressed over the course of the study (drop in 10% FVC).
Differences in FVC, FEV1 and DLCO % predicted values were detected.
Additionally, CPI and total lung capacity showed statistical differences. CT =
Computer Tomography, FEV1 = Forced Expiratory Volume in One Second, FVC
= Forced Vital Capacity, DLCO = Diffusing Capacity of the Lungs for Carbon
Monoxide, CPI = Composite Physiologic Index
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Table 2. FEV1/dFVC Ratio Patient Cohort Baseline Characteristics
Vicary et. Al., Unpublished

The cohort of 85 idiopathic pulmonary fibrosis (IPF) patients who achieved >10%
decline in the FVC during the study were compared for baseline characteristics in
placebo versus treatment group. No significant differences were detected between
the placebo and treatment groups. CT = Computer Tomography, FEV1 = Forced
Expiratory Volume in One Second, FVC = Forced Vital Capacity, DLCO = Diffusing
Capacity of the Lungs for Carbon Monoxide, CPI = Composite Physiologic Index
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Spirometry Value Distribution
The patient cohort displayed Gaussian distribution for baseline values of
FEV1, FVC and FEV1/FVC ratio (Figure 44). Baseline values included an average
FEV1 of 2.3 liters (L) (73.7% predicted), average FVC of 3 liters (68%
predicted) and an average %FEV1/FVC of 77.26%. Average baseline value of
FEV1/dFVC was 2.6 with two outliers skewing the histogram (one with ~600,
another with ~93). By nature of the formula, it is possible for very high numbers to
happen with the FEV1/dFVC, especially if the predicted FVC and actual FVC are
very close.

Primary Outcomes
Time to 10% decline in FVC was compared to 10% decline in FEV1/dFVC.
FEV1/dFVC detected a 10% decline significantly earlier then FVC alone (Table 3)
(Stuart-Maxwell Test X2(3) = 23.58, p<0.001). The time to 10% decline in FVC was
compared to 10% drop in FEV1/dFVC (Figure 45). 42.5% of the patients had a
10% drop detected in FVC and FEV1/dFVC at the same visit. 25% of patients were
detected 15 weeks earlier, while another 25% of the patients were detected 30
weeks earlier. Cumulatively, over 50% of the patients had a 10% drop in
FEV1/dFVC detected at least 15 weeks (1 visit) earlier.

Secondary Outcomes
Investigating the potential role of spirometry values on clinical outcomes, a
drop in 10% FVC and FEV1/dFVC ratio were analyzed as predictors for re-
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hospitalization and death. An increase in deaths was detected in the cohort who
dropped more than 10% in their FVC (Table 4). No differences found between
control and treatment cohorts using the FEV1/dFVC ratio were found (Table 5).
Additionally,

Kaplan-Meier

comparison

curves

were

computed

for

death/hospitalization using FVC alone or FEV1/dFVC, but neither showed enough
efficacy to be used clinically (Figure 46). Lastly, patients were compared weekly
for placebo vs treatment or those who had a %FVC drop at the same time as %
FEV1/dFVC vs later. Neither comparison showed a significant difference (Figure
47).
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Figure 44. Distribution
of FEV1, FVC, FEV1/FVC and
FEV1/dFVC Values
Vicary et. Al., Unpublished

The FEV1/dFVC patient cohort displayed Gaussian distribution for baseline values
of FEV1, FVC and FEV1/FVC ratio. (A) Baseline values included an average FEV1
of 2.3 liters (L) (73.7% predicted) with a range from 1-5 L. (B and C) Patients had
an average FVC of 3 liters (68% predicted) with a range of 1-5 L and an average
%FEV1/FVC of 77.26%. (D) Average baseline value of FEV1/dFVC was 2.6 with
two outliers skewing the histogram (one with ~600, another with ~93).
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Time to 10% loss
FEV1/dFVC

15 weeks
30 weeks
45 weeks
60 weeks
Column
Total

OVERALL
Time to 10% loss FVC
15 weeks 30 weeks 45 weeks 60 weeks
17
12
16
7
0
7
7
5
0
0
9
2
0
0
0
3
17

19

32

17

Row Total
52
19
11
3
85

FEV1/dFVC FEV1/dFVC FEV1/dFVC
FVC 10% FVC 10% FVC 10% 10% loss
10% loss 10% loss 10% loss
loss earlier loss earlier loss earlier at same
earlier by 1 earlier by 2 earlier by 3
by 3 visits by 2 visits by 1 visit
visit
visit
visits
visits

Table 3. FEV1/dFVC Ratio Decreases by 10% Earlier Then FVC Alone
Vicary et. Al., Unpublished

Time to 10% decline in FVC was compared to 10% decline in FEV1/dFVC.
FEV1/dFVC detected a 10% decline significantly earlier then FVC alone (StuartMaxwell Test X2(3) = 23.58, p<0.001).
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Figure 45. FEV1/dFVC Earlier Detection in Patients by Weeks
Vicary et. Al., Unpublished

The time to 10% decline in FVC was compared to the time of 10% drop in
FEV1/dFVC. Over 75% of patients had a 10% decline detected in FEV1/dFVC by
30 weeks (3 visits), where a 10% drop in FVC had been detected in less than 50%
of patients.
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Table 4. Drop in 10% FVC as Predictor of Hospitalization/Death
Vicary et. Al., Unpublished

The PANTHER trial patients were separated by whether their pulmonary fibrosis
progressed over the course of the study (drop in 10% FVC). Predicting rehospitalization and death endpoints showed a significant difference in deaths
between patients who did and did not drop in 10% FVC.
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Table 5. FEV1/dFVC Ratio as Predictor of Hospitalization/Death
Vicary et. Al., Unpublished

The cohort of 85 patients who achieved >10% decline in the FVC during the course
of the study were compared for endpoint characteristics in placebo versus
treatment group. Predicting re-hospitalization and death endpoints showed no
difference between FEV1/dFVC ratio and FVC.
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Figure 46. Death and Hospitalization Receiver Operating Characteristics
(ROC) Curve of FEV1/dFVC and FVC Alone
Vicary et. Al., Unpublished

Receiver operating characteristics (ROC) curves compare the FEV1/dFVC ratio
versus FVC alone in regards to sensitivity and specificity as a predictor of death
and re-hospitalization. FEV1/dFVC ratio and FVC alone showed no difference and
neither were accurate enough predicting death and hospitalizations to be used
clinically.
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Figure 47. Patient Hospitalization/Death by Weeks
Vicary et. Al., Unpublished

(A) Using FEV1/dFVC ratio, there was no difference in survival detected between
treatment and placebo groups. (B) No difference in survival between 10% drop in
FVC and FEV1/dFVC detected at the same visit or FEV1/dFVC detected earlier
were detected.
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6.3 Discussion

With IPF affecting so many people around the world and having an average
survival rate of 3 years, the need for better treatments is imperative. The FDA
recently approved two drugs for the treatment of IPF and several other drugs are
in development [287, 288]. Creating more sensitive markers for IPF progression
can allow drug trials to be completed earlier, allowing for more efficient FDA
approval. Better disease markers will also allow physicians to determine the best
treatment regimen for patients.
The current paradigm on the progression of pulmonary fibrosis has always
included loss of lung volume due to loss of lung elasticity due to the expansion of
fibrotic foci, but restrictive airway remodeling has been overlooked. The research
presented here and by others show that including restrictive airway measurements
might increase the specificity and sensitivity of spirometry as a diagnostic marker
for fibrosis progression and survival. Nishiyama et. Al. showed lower FEV1/FVC
(below 83%) was associated with increased patient survival [294]. Additionally,
shown here, restrictive airway (FEV1) with lung volume (FVC) allowed for earlier
detection of 10% decline then FVC alone.
There are limitations to this study. Co-morbidities may affect the ratio, such
as combined pulmonary fibrosis and emphysema diagnoses which showed to
lower the FEV1/FVC ratio [304]. Additionally, only progressive patients (drop >10%
FVC) were used for analysis. Including non-progressive patients would not have
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allow us to compared our primary endpoints (FEV1/dFVC and FVC) for patients
that did not drop 10% in FVC by the end of the study.
Multiple values and tests may end up being used in clinical practice for
measuring progression, including spirometry and biomarkers [305]. Daily FVC
values recently showed significance in predicting patient survival [292].
Additionally, the 6-minute walk test (6MWT) has shown to be associated with
dyspnea and quality of life scores, but no significant difference was detected
between 6MWT and FVC [290]. We hope research presented here will help to
advance the ability to track progression of IPF in patients.
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CHAPTER VII

PULMONARY FIBROSIS IN HERMANSKY-PUDLAK SYNDROME

7.1 Introduction

Pulmonary fibrosis is characterized by the accumulation of fibroblasts and
the unrestrained chaotic expression and deposition of connective tissue matrices
leading to effacement of the pulmonary architecture with loss of lung function.
Environmental factors (e.g. asbestos and silica exposure), genetic factors (e.g.
surfactant-related proteins and telomerase), and viral factors (herpesvirus) have
been associated with the development of lung fibrosis, while other factors are
believed to contribute to its progression (e.g., allergens, tobacco) [1, 13-17].
However, pulmonary fibrosis often occurs in subjects where a cause cannot be
identified [1].
Despite the growing association of genetics with pulmonary fibrosis, the
mechanisms by which abnormalities in these genes lead to alterations in cellular
functions; extracellular matrix expression, deposition and degradation; production
of profibrotic growth factors; and, ultimately, disruption of lung homeostasis and
pulmonary fibrosis remain poorly understood.
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One genetic disorder associated with highly penetrant pulmonary fibrosis is
the Hermansky-Pudlak Syndrome (HPS), a rare autosomal recessive disorder
characterized by oculocutaneous albinism, bleeding diathesis, granulomatous
colitis, and, in many cases, pulmonary fibrosis. HPS affects approximately
1:500,000-1,000,000 people worldwide, and has been reported in individuals from
India, Japan, China, United Kingdom, Western Europe, Pakistan, Canada and the
United States [306, 307]; the HPS Network registry also includes patients from
Israel, Australia, Hungary, Mexico, Brazil, Peru, Qatar, and Bolivia, among others.
Although HPS is a very rare disease, it is relatively common in Puerto Rico, where
the prevalence of HPS-1 is estimated to be about 1:1,800 in the Northwest region
of the island, accounting for approximately 50% of all cases globally [308].
Unfortunately, the average life expectancy of HPS patients is 40-50 years and
there are currently no effective treatments, with over 70% of patients dying due to
complications directly related to the disease [309].
Here, we summarize the current understanding of the pathogenesis of HPS
and its clinical manifestations and management, while discussing recent
discoveries that might lead to the identification of potential targets for intervention
and effective therapies in the future. This review is intended to raise awareness
about pulmonary fibrosis in HPS, and prompt interest in further research in this
syndrome, research that could also hold the key for understanding more common
pulmonary fibrosing disorders.
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7.2 Genetic and Functional Abnormalities in Hermansky-Pudlak Syndrome
(HPS)

HPS was first described in 1959 by Dr. Frantisek Hermansky and Dr. Paulus
Pudlak who identified two patients with oculocutaneous albinism and bleeding
diathesis in Czechoslovakia [310]. HPS is a non-sex-linked autosomal recessive
disorder with no known disease manifestations in carriers. Ten types of HPS have
been defined by nine unique genes distinguished by their signs, symptoms, and
genetic cause; and in most cases, each subtype has more than one variant (Table
6) [307, 311-313]. HPS-1 is the most common and generally severe subtype. HPS2 and -4 also have severe manifestations and HPS-10 has neurological changes,
while patients with the other variants (HPS-3, 5-9) generally manifest somewhat
milder symptoms [314].
In Puerto Rico, HPS-1 and -3 are the most common subtypes. This is
because certain populations in Puerto Rico were established by a very small
number of individuals who carried the silent gene (founder effect) [308]. One in
twenty-one Puerto Ricans in the Northwest of the Island are carriers of the gene
mutation (>160,000 people) [315]. Thus, it is estimated that 7–8 children with HPS
will be born on the island each year [308]. In Puerto Rico, HPS-1 arises mainly due
to a duplication/frameshift (16-base pairs) on exon 15 of the HPS1 gene,
accounting for 45% of all HPS cases globally and most cases in the island [308,
316]. Outside of Puerto Rico, HPS-1 is caused by different mutations within the
HPS1 gene loci [317]. Another 25% of HPS cases in the island occur from a
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Human

Gene

Type

NCBI

Human

Protein

RefSeq

Chromosome

Complexes

Location
HPS1

HPS1

NM_000195

10q24.2

BLOC-3

HPS2

AP3B1

NM_003664

5q14.1

AP-3

HPS3

HPS3

NM_032383

3q24

BLOC-2

HPS4

HPS4

NM_022081

22q12.1

BLOC-3

HPS5

HPS5

NM_0181507

11p15.1

BLOC-2

HPS6

HPS6

NM_024747

10q24.32

BLOC-2

HPS7

DTNBP1

NM_032122

6p22.3

BLOC-1

HPS8

BLOC1S3

NM_212550

19q13.32

BLOC-1

HPS9

BLOC1S6

NM_012388

15q21.1

BLOC-1

HPS10

AP3D1

NM_003938

19p13.3

AP-3

Table 6. Human Hermansky-Pudlak Syndrome (HPS) Variants
Vicary et. Al., 2016

HPS is a non-sex-linked autosomal recessive disorder with no known disease
manifestations in carriers. Nine types of HPS have been defined by nine unique
genes distinguished by their signs, symptoms, and genetic cause.
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deletion (3,904-base pairs) in HPS3. HPS3 is believed to have developed in the
1880-1890s in the central mountainous region of Puerto Rico [308, 316, 318].
Consistent with the genetic drift expected over hundreds of years, more recent
studies have suggested that carrier frequencies for HPS1 and HPS3 are similar
across Puerto Rico [308, 319].
Exactly how the genetic mutations in HPS genes lead to all manifestations
of the disease is unknown. HPS genes code for HPS proteins, which form
complexes termed biogenesis of lysosome-related organelles complexes (BLOCs)
(Figure 48) [320-322]. Lysosome related organelles (LROs) perform specialized
functions in the sorting and trafficking of specific cargo. BLOC-3, a complex which
includes the HPS1 and HPS4 proteins and others, functions as a Rab32/38
guanine nucleotide exchange factor; these are proteins capable of activating small
GTPases, thereby affecting intracellular signaling and downstream targets.
HPS mutations impair the biogenesis and function of LROs, which explains
some disease manifestations. For example, LRO dysfunction affecting pigmentproducing cells (termed melanocytes) is responsible for albinism. Specifically, in
melanocytes, activated Rab32/38 is needed for the transport of tyrosinase and
tyrosinase related protein 1 (TYRP1) from early ribosomes to melanosomes; this
likely represents a key step and its disruption has been shown to lead to the
oculocutaneous manifestations of HPS-1 [323]. In over 80% of patients with HPS,
this is manifested by lentigines, while a small percentage of patients may also
develop solar keratosis, squamous cell, or basal cell carcinomas [315]. Decreased
pigmentation in the eyes causes legal blindness in most patients, as well as
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Figure 48. Lysosomal-Related Organelles (LROs) in HPS
Vicary et. Al., 2016

Lysosome-related organelles (LROs) are a group of cell type-specific subcellular
compartments that share some features with endosomes and lysosome, but also
develop unique properties as they harbor specialized cargoes. Many of the clinical
manifestations of HPS are explained by abnormalities in the formation and
trafficking of LROs, including albinism (melanosomes), bleeding (platelet dense
granules), and pulmonary fibrosis (likely related at least in part to abnormal
lamellar body genesis in type II alveolar epithelial cells).
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photophobia, impaired dark adaptation, and nystagmus.
Similarly, defects in platelet LROs leads to bleeding diathesis due to
inhibition of the formation of platelet dense bodies [324]. In type II alveolar
epithelial cells of the lung, Rab38 helps maintain lamellar body morphology and
surfactant homeostasis [323]. The role of this defect in the development of
pulmonary fibrosis is not known, but it is intriguing to note that abnormalities in
surfactant proteins have been identified in idiopathic pulmonary fibrosis and related
interstitial lung disorders [323, 325, 326]. Disease mechanisms remain uncertain
for the occurrence of granulomatous colitis that has also been reported in
approximately 15% of HPS patients, not necessarily tracking with occurrence of
subtype risk for pulmonary fibrosis.
Accumulation of an amorphous lipid-protein complex, ceroids, which
increases with age in patients with HPS has been speculated to be a potential
trigger for the development of tissue inflammation, possibly contributing to some
of the multi-organ manifestations of HPS [315, 322, 327, 328].

7.3 HPS and Pulmonary Fibrosis (HPS-PF)

In a joint statement of the American Thoracic Society and European
Respiratory Society, HPS-related pulmonary fibrosis (HPS-PF) and idiopathic
pulmonary fibrosis (IPF) are considered similar entities (albeit with distinct causes)
since both can show similar histological patterns [41]. IPF occurs spontaneously
in most patients, but research has uncovered some genetic mutations in surfactant
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proteins, mucins, and telomerases that are considered relevant [1, 14-17]. Only
HPS-1, -2 and -4 are associated with the development of pulmonary fibrosis, but
100% of HPS-1 patients will develop HPS-PF [328]. Both HPS-PF and IPF are
characterized by irreversible and progressive fibrosis of the lung parenchyma and
interalveolar septa, ultimately leading to death from respiratory failure. Similar
symptoms are found in HPS-PF and IPF, including increased dyspnea initially
manifested as exercise intolerance that progresses to dyspnea at rest and the
need for supplemental oxygen over time.
One intriguing, but important difference between IPF and HPS-PF is the age
at which pulmonary fibrosis is detected. Spontaneous IPF manifests in patients
mostly over age 50 (this is not the case for familial IPF), while HPS-PF occurs
much earlier (30-40 years). Another major difference is that the average survival
time after diagnosis differs with IPF carrying a dismal 3-year survival rate of 50%,
while HPS patients live approximately 10 years after diagnosis [5, 329]; this might
reflect earlier ascertainment and not differing natural history.
Current understanding of the pathogenesis of pulmonary fibrosis points to
epithelial cell dysfunction as the inciting cause of the disease. Several intracellular
trafficking processes might be affected leading to endoplasmic reticulum stress
and apoptosis caused by environmental exposure to injurious agents (e.g., viral
infection, recurrent aspiration of gastric contents) or through genetic abnormalities
(e.g., surfactant proteins). Injured or dysfunctional epithelial cells are proposed to
promote the accumulation of fibroblasts that are responsible for the excessive
deposition of extracellular matrices [18]. The origins of these fibroblasts are
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unclear, but combinations of mechanisms are hypothesized, including the
transdifferentiation of epithelial cells (epithelial-mesenchymal transformation), the
differentiation of fibrocytes and stem cells, and the proliferation of resident
fibroblasts [42].

Regardless of their source of origin, the interplay between

dysfunctional epithelial cells and activated fibroblasts (also termed myofibroblasts
because of their expression of smooth muscle cell markers) seems to drive
unrestrained collagen deposition and tissue scarring.

Underlying amplifying

factors like aging and epigenetic changes are thought to further perpetuate the
progressive nature of pulmonary fibrosis [18].
There is a growing body of work dissecting the mechanisms of pulmonary
fibrosis in HPS. HPS gene products are ubiquitously expressed and thus many
cell types have been potentially implicated as contributors to the pathogenesis of
HPS-PF. First, there is strong evidence that macrophage-mediated inflammation
precedes pulmonary fibrosis in HPS patients. Bronchoalveolar lavage (BAL) fluid
of HPS-PF patients contained increased total cell counts and alveolar
macrophages [330], at a time when patients still had relatively preserved lung
function. Furthermore, alveolar macrophages from HPS patients have been shown
to be constitutively activated, expressing excess cytokines and chemokines when
studied ex vivo [330]. BAL fluid from HPS patients also had elevated levels of
several cytokines, including chemokine (C-C motif) ligand 2 (CCL2/MCP-1),
macrophage colony-stimulating factor (M-CSF), and granulocyte-macrophage
colony-stimulating factor (GM-CSF) [330]. Interestingly, elevation of CCL2 levels
was directly associated with the progression of HPS-PF; a similar association has
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been observed in IPF and animal models of pulmonary fibrosis [331, 332].
Abnormalities in fibroblasts have also been reported including increased
expression of galectin-3, a β-galactoside-binding lectin with profibrotic effects
[333]. In addition, patients with HPS-PF have been found to have increased
numbers of circulating CXCR4-positive fibrocytes compared to subjects with HPS
without lung disease or healthy control subjects [334]. Increasingly, as suggested
for IPF, studies point to the type II alveolar epithelial cell as central in the
pathogenesis of HPS pulmonary fibrosis. Lamellar bodies (responsible for
producing surfactant proteins) are a type of LRO [326], making alveolar epithelial
cells a good candidate for dysfunction in HPS.
As HPS lung tissue is limited in availability for research due to disease rarity
and contraindication to lung biopsy because of the bleeding diathesis, much HPS
research to date has been conducted in murine models, which also afford
opportunities for access to cells and tissues, and genetic manipulations not
possible in humans. Murine models of HPS reliably share many aspects of the
human disease including hypopigmentation, deficiency of platelet dense granules,
and abnormalities of type II alveolar epithelial cells and alveolar macrophages
(Table 7 and Table 8). Mice have more than 16 different genes with HPS-like
phenotypes [335], though many of the gene functions are unknown. At least six
mouse models have the orthologous mutations to the human genes [336-341].
Interestingly, murine models of HPS-1 (Pale ear) and HPS-2 (Pearl) show
activation of alveolar macrophages in the lung, but not in the blood or peritoneum
[342, 343]. Pale ear HPS1 mice do not develop spontaneous fibrosis, but have
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Mouse Model

Mouse RefSeq

Mouse Chromosome Location

Pale Ear

NM_019424

Chr19

Pearl

NM_009680

Chr13

Cocoa

NM_080634

Chr13

Light Ear

NM_138646

Chr5

Ruby eye-2

AF534396

Chr7

Ruby eye

NM_176785

Chr19

Sandy

NM_025772

Chr13

Zebrafish

NM_001025476

Chr15

Pallid

NM_019788

Chr2

Muted

NM_139063

Chr13

Cappuccino

NM_133724

Chr5

Mocha

NM_007460

Chr10

Table 7. Mouse models of HPS
Vicary et. Al., 2016

There are several murine models of HPS. Each model of HPS has been defined
by a unique gene and a name based off the specific characteristics.
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Physiology/Cellular Abnormality

Mouse HPS Gene(s)

Hypopigmentation

All

Prolonged Bleeding

All

Lung Disease

HPS1/HPS2 Double Mutant,
Pldn

Decreased Lysosomal Enzyme Secretion

Most

Decreased CTL Granule Secretion

Rab27a

Dysregulated Mast Cell Granule Secretion

HPS6

CD1d Deficiency

HPS2

NK Cell Dysfunction

HPS1, Pldn, rp

Decreased Proplatelet Production

Rabggta

Night Blindness

HPS2

Susceptibility to Anesthetics

Pldn, rp

Protection from Atherosclerosis

HPS4, HPS6

Increased Emperipolesis

Rabggta

Otolith Deficiency

Ap3d, Pldn, mu

Hippocampal Granule Deficiency

Ap3d

Decreased Lifespan

Rabggta, HPS2, HPS3, Pldn

Table 8. Phenotype and cellular abnormalities in mouse models of HPS
Vicary et. Al., 2016

Murine models of HPS reliably share many aspects of the human disease including
hypopigmentation, deficiency of platelet dense granules, and abnormalities of type
II alveolar epithelial cells and alveolar macrophages.
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higher baseline collagen deposition and show increased inflammation and
collagen expression in response to silica challenge [342, 344, 345]. In response
to bleomycin, HPS-1 and HPS-2 mice developed fibrosis significantly earlier and
to a greater extent than wildtype mice [343]. Also, higher levels of transforming
growth factor-β were detected in bleomycin-treated HPS mice.

However, it is

intriguing that spontaneous lung fibrosis does not occur in these single mutant
models, suggesting that other factors and secondary hits are required to develop
the full manifestations of the disease. With aging, spontaneous fibrosis has been
reported in a HPS double-mutant model, generated by mating HPS-1 and HPS-2
mice [346]. Alveolar epithelial cell dysfunction in HPS remains under study, but
recent publications implicate alveolar epithelial cell apoptosis [346, 347],
Chitinase-3-like-1 and its receptors [348], and autophagy [349] as potential
mechanisms. Macrophage-mediated inflammation is also present in HPS mouse
models. However, murine bone marrow transplant studies have demonstrated that
macrophage abnormalities and fibrotic susceptibility are likely due to epithelial
dysfunction with type II alveolar cell death, not intrinsic macrophage defects [347].
This is important because it suggests that HPS-PF could be driven more than just
macrophage mutations. Collectively, these studies indicate the role of HPS mice
as an experimental model for HPS disease, and identify mechanisms that are likely
also relevant for other fibrosing lung diseases.
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7.4 Diagnosing HPS and HPS-PF

The diagnosis of HPS includes the documentation of oculocutaneous
albinism and platelet storage pool deficiency [328]. HPS patients are potentially
identified shortly after birth by their albinism, though the degree of
hypopigmentation is variable.

Other individuals are not diagnosed until after

experiencing other disease complications such as excessive bleeding after
circumcision or easy bruising; over 75% of patients have bruises at the time of
clinical examination. Bleeding time is often quite prolonged, but is not
recommended for diagnostic or screening due to poor specificity and lack of
prognostic value [350]. Ophthalmologists might be the first to suggest testing for
HPS due to diminished vision, with transillumination of the iris in addition to
nystagmus and strabismus.
Testing for HPS is currently limited by complexity, expense, and availability
of specialized diagnostics required for confirmation. The gold standard test for the
platelet abnormality in HPS is analysis by whole mount electron microscopy for the
absence of dense bodies [351]. Testing of platelet aggregation following platelet
stimulation with adenosine diphosphate or epinephrine (using a platelet
aggregometer) [352] provides a less specific alternative. Genetic testing plays a
growing role in diagnosis, and it is important for determining HPS subtype (and
prognosis). Such assessments are also essential to determine the numbers of
individuals with distinct HPS subtypes in any given community. However, genetic
testing has not been widely implemented for HPS due to the cost of next-
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generation sequencing [353]. Genetic testing could be used to help identify specific
mutations as the price of next-generation sequencing decreases. Not all patients
with HPS have identified genetic mutations though, suggesting that there are
additional HPS disease-causing genes to be discovered. In the absence of genetic
confirmation, patients with the classic manifestations of the syndrome (e.g.,
albinism with bleeding disorder, colitis or pulmonary fibrosis) should be considered
to have HPS unless proven otherwise.
The progression of HPS-PF is characterized by the development of
dyspnea and increasingly debilitating hypoxia. Thus, it is recommended that all
patients with HPS-1, -2, and -4 be evaluated for lung function during adolescence
and yearly thereafter [328].

Pulmonary physiology is best evaluated with

pulmonary function tests including diffusing capacity for carbon monoxide. Early
evidence of pulmonary fibrosis might be manifested by a decrease in force vital
capacity and lung volumes (indicating a restrictive defect) and reduced diffusing
capacity for carbon monoxide, which is typical of fibrosing lung disorders. A sixminute walk test (6MWT) using a portable oximeter should also be considered as
hypoxemia may only be detected during exertion in early stages of the disease.
HPS-PF is best evaluated by high-resolution computed tomography.
Common changes include ground-glass opacities, reticulation of interstitial spaces
and, with advanced disease, loss of lung volume, honey-combing, and traction
bronchiectasis [314, 354, 355]. The predominant findings in HPS-PF occur within
the lung periphery and progress towards the central portion of the lung as the
disease progresses. The most common abnormalities in cases of minimal severity
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are interlobular septal thickening, reticular opacities, ground-glass opacities and
subpleural honey-combing. As the disease progresses, reticular opacities and
subpleural honeycombing are present to a greater extent. Additionally, a wider
range of findings including bronchiectasis, peribronchovascular thickening, and
pleural thickening have been reported. In severe cases, sub-pleural honeycombing
and bronchiectasis are more common, and subpleural reticular opacities, groundglass opacities, and peribronchovascular thickening are also present [322, 354,
356]. Thus, although the pattern of pulmonary fibrosis in HPS-PF may be similar
to that observed in IPF, several findings are not consistent such as ground glass
opacification and pleural thickening (Figure 49).
In contrast to cases being evaluated for IPF and related disorders, a lung
biopsy is not recommended in suspected HPS-PF due to the bleeding diathesis.
Imaging studies and pulmonary function tests could be conducted to track
progression of fibrosis. Bronchoscopy has been used for research purposes, but
does not have proven benefits for HPS diagnosis. In short, the diagnosis of HPSPF differs from that of IPF in that lung biopsy is not recommended, and a high level
of suspicion is required at an early age in patients with HPS-1, -2 and -4.

7.5 Treatment and Management of HPS-PF

At the moment, no Federal Drug Agency (FDA) approved interventions are
specifically designated for the treatment of HPS and HPS-PF, and progress in this
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B

C

D

Figure 49. Examples of Chest CT findings in Subjects with HPS-PF
Vicary et. Al., 2016

(A) Case of 50 years old patient with HPS-1 showing mild changes consistent of
subpleural infiltrates. (B) Case of 41 years old patient with central infiltrates. (C)
Ground glass opacification. (D) Case of 31 years old patient with mid to upper
lung infiltrates (D). The images used were from patients consented under the
Rare Lung Diseases Consortium HPS study under Vanderbilt University IRB
protocol number 150104.
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area has been hindered by the lack of large placebo-controlled, randomized clinical
trials. Similar to IPF, corticosteroids have not shown clinical efficacy and are not
recommended for HPS-PF. Thus, until safe and effective treatment strategies are
developed, lung transplantation may remain the only effective treatment [319, 354,
357].
As is the case for IPF, treatment relies on preventive care and support as
needed. Patients with hypoxemia should be provided supplemental oxygen.
Infection prophylaxis is also critical; thus, influenza and 13-valent and 23-valent
pneumococcal vaccinations are recommended, and administered with caution to
avoid intramuscular bleeding. Additionally, a 5 year polysaccharide booster
vaccine may be beneficial [358]. Avoidance of cigarette smoke and other
pulmonary irritants is critical, while daily exercise is recommended to avoid
deconditioning. HPS patients should avoid unprotected eye and skin exposure to
the sun due to their albinism. Menometrorrhagia is common in women, but can be
lessened with medication [315, 328]. Further, patients with HPS should avoid
aspirin and non-steroidal anti-inflammatory drugs due to platelet inhibition.
Extensive injuries should prompt a hospital visit and consultation of a hematologist.
The approval of two new anti-fibrotic drugs, pirfenidone and Nintedanib, for
the treatment of IPF, has prompted new interest in identifying drugs capable of
reversing or, at the very least, halting the progression of HPS-PF. It should be
emphasized that these drugs are not curative, but instead appear to slow down the
decline of lung fibrosis in IPF. Pirfenidone, a small molecule capable of inhibiting
TGF-b, showed success in slowing pulmonary dysfunction in clinical trials with IPF
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patients [50, 52]. Interestingly, ex vivo, pirfenidone showed significantly decreased
inflammatory cytokines in HPS patient alveolar macrophages [330]. An initial
clinical trial of HPS-1 patients with pirfenidone showed no significant slowing of
fibrosis progression by forced vital capacity (FVC) [329]. Secondary analysis of
this patient population showed patients with an initial FVC value >50% of expected
had significant decrease in the progression of their pulmonary fibrosis.
Disappointingly, a follow-up study with HPS-1 and -4 patients with milder disease
showed no significant benefit and was stopped prematurely, but it was likely
underpowered [359]. Future clinical studies will be needed in HPS to identify
effective treatments.
Considering the genetic basis for the development of HPS, one would
predict that gene transfer might be successful in treating this disease. In fact,
others have used lentiviruses for the transfer of the HPS1 gene into human dermal
melanocytes in vitro and shown correction of the expression and function of the
HPS1 gene in these cells [325]. However, difficulties in gene transfer methods in
the lung, particularly to the alveolar epithelium, hamper progress in this area, and
much still needs to be learned before gene therapy is considered for potential
correction of BLOC-3 dysfunction.

7.6 Summary and Discussion

HPS is an autosomal recessive disorder caused by defects in the
biogenesis of lysosome-related organelles (LROs) and intracellular trafficking.
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Even though HPS is considered an orphan disease (affecting less than 200,000
individuals in the U.S.), its consequences are devastating and often affect young
individuals. The epidemiology, natural history, clinical heterogeneity, and best
approach to pulmonary monitoring in this population remain insufficiently
understood. Despite significant scientific advances, additional research is needed
to identify the mechanisms by which the genetic mutations responsible for HPS
result in the clinical manifestations of the syndrome. In vitro and ex vivo studies
with tissue, cells, blood, bronchoalveolar lavage fluid and other samples collected
from patients, as well as in vivo studies in animal models hold promise for
determining relevant biological pathways for intervention. Well-conducted placebo
controlled and randomized clinical trials will accelerate the evaluation of new antifibrotic agents and other interventions with therapeutic potential. Undoubtedly, the
small number of patients affected by HPS will make large-scale studies difficult.
Currently, two clinical trials are recruiting HPS-PF patients to hopefully develop
better biomarkers for disease progression (NCT02368340, NCT00001456). In the
end, such investigations should lead to effective and safe therapies for HPS and
its manifestations, especially pulmonary fibrosis. In the meantime, we must find
ways to address the clinical needs of these patients. The diagnosis, management,
and follow-up of these patients will require the establishment of multidisciplinary
centers of excellence staffed with experts in this area. In Puerto Rico, the
increased incidence of HPS warrants the development of such a center.
Considering that centers with capabilities for lung transplantation are not available
in Puerto Rico, connections with centers in the U.S. with transplantation capability
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is important since this procedure is currently the only option for a significant
number of patients with HPS-PF.
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CHAPTER VIII

SUMMARY AND DISCUSSION

Pulmonary fibrosis affects millions worldwide. This condition is associated
with excessive accumulation of activated fibroblasts and chaotic deposition of
collagens and other extracellular matrices that lead to obliteration of the healthy
lung structure. In many cases, this condition is progressive, thereby leading to lung
dysfunction and, ultimately, respiratory failure and death. This is true for IPF, a
stereotypical fibrosing lung disorder that affects over 100,000 patients in the U.S.,
and carries a poor prognosis, with an average survival limited to 3 years after
diagnosis [1, 2]. Although two FDA-approved drugs have recently reached the
market, they do not improve lung function and long term efficacy is uncertain [50,
52, 54]. Thus, studies directed at better understanding the pathophysiology of this
condition and its early detection are needed.
Exactly

how

tobacco

contributes

to

this

condition

is

unknown.

Understanding the pathogenesis of tobacco-related diseases is a significant public
health problem, with approximately 40 million Americans smoking cigarettes.
Tobacco smoke is thought to contribute to the development and progression of
pulmonary fibrosis as many patients with IPF and related fibrosing lung disorders
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are current or ex-smokers [1, 23-25]. This research focused on a major
component of tobacco, nicotine, because of recent studies showing that, in
addition to promoting addiction, nicotine may stimulate cell proliferation, affect
redox reactions, influence inflammation, and promote tissue remodeling during
embryogenesis. Thus, this dissertation set out to study if nicotine promotes ECM
expression in pulmonary fibroblasts, the main effector cell in pulmonary fibrosis,
and the mechanisms responsible for these effects; examine the impact of nicotine
on injury-induced lung fibrosis; and determine if nicotine influences survival after
injury. We also set out to test the prognostic impact of non-invasive measures
capable of detecting early progression of fibrosis. Multiple in vitro and in vivo
models as well as national databases were used to address these complex areas.
We found that nicotine promotes the expression of fibronectin and type I
collagen, ECM components highly expressed in injured tissues and implicated in
wound healing and disrepair. Interestingly, we identified a7 nAChRs as the
receptors responsible for these events. Based on the above, we predicted that
nicotine would enhance fibrosis in a bleomycin-model of lung injury. Nicotine did
enhance fibrosis in this model but, interestingly, it appeared to be both harmful and
protective as higher doses of bleomycin increased mortality, yet nicotine reduced
this harmful effect. The latter was mediated via a7 nAChRs as well. Finally, we
defined a new formula obtained through lung physiological testing that may be
useful in the clinical arena for early detection of progression of lung fibrosis. These
findings are considered novel and important for the following reasons.
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First, our data provide a mechanistic description that links tobacco exposure
to the development of fibrosing lung disease. However, it is important to note that
nicotine does not cause lung fibrosis. Instead, it promotes relative alterations in the
composition of the ECM without altering the overall tissue architecture. This effect,
termed transitional remodeling, may not create physiological abnormalities at
baseline, but we speculate that it may render the host susceptible to disrepair after
a second insult (e.g., infection or inhalation of toxicants). This is an intriguing
concept as it suggests that other conditions might promote transitional remodeling.
In fact, it has been reported that chronic alcohol abuse might lead to similar
changes [360]. Of note, aging is also associated with transitional remodeling. This
is highly relevant since aging is yet another factor linked to the development of IPF
[361]. Thus, identifying challenges like nicotine, that can promote transitional
remodeling would be important as these observations might allow us to identify
those which are susceptible to pulmonary fibrosis after injury. Of course, genetics,
extent of injury, nature of the insult, and other factors are likely to contribute, and
this explains why not all smokers develop pulmonary fibrosis.
The concept of transitional remodeling is also important because it raises
questions as to how this process may promote disrepair. Our work shows that
monocytic cells cultured atop of ECMs derived from nicotine-treated lung
fibroblasts express high levels of the pro-inflammatory cytokine IL-1b. Thus, we
speculate that chronic nicotine exposure might promote transitional remodeling
that does not cause disease at baseline, but may promote disrepair after injury by
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stimulating excessive inflammation induced through its interaction with immune
cells recruited to the lung after a second insult (Figure 4).
Exposure to tobacco smoke is historically pro-inflammatory, exposing the
lung to thousands of compounds and heat. Conversely, nicotine alone is typically
considered anti-inflammatory with activation of the cholinergic anti-inflammatory
pathway [362]. This belief is conflicted by others demonstrating nicotine can
contribute to disease by stimulation of inflammation [363]. Together, the role of
nicotine is still being investigated, but the differential effects of nicotine on
inflammation may depend on dosage, organ and cells exposed. This is supported
by the presence of a7 nAChRs present on several different cell types present
throughout the body. Thus, nicotine may directly reduce inflammatory processes
in immune cells, but the production of transitional matrices indirectly induces
inflammation. At baseline, the anti-inflammatory effects of nicotine might be helpful
to avoid disrepair, but this might render the host susceptible to infection. On the
other hand, nicotine’s pro-inflammatory effects might be helpful to combat
infection, while promote disrepair and tissue fibrosis. Fine tuning of these
processes will be required to target cholinergic signaling in ways that promote
healthy rather than a fibrotic lung state.
This work also suggests that the newly deposited transitional matrix may
affect other pulmonary cells involved in the reparative process such as epithelial
cells, lung fibroblasts, and endothelial cells. We speculate that by altering the
underlying ECM, the injured lung is less able to return to its original structure after
injury. If true, preventing the development of a transitional matrix might be
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therapeutic. On the other hand, it is conceivable that transitional matrices are
necessary for adequate repair after certain (and perhaps less devastating) insults.
Thus, further investigations are needed to determine the true role of transitional
matrices prior to engaging in work directed at targeting this process in the clinical
arena. Nevertheless, our work provides a model and a framework on which to
design such studies.
Additionally, an important aspect of the concept of transitional remodeling
is whether it affects the lung at baseline in ways that promote disrepair other than
via inflammation. We hypothesized that perhaps nicotine-induced transitional
remodeling may affect tissue stiffness. The latter is important when considered
against emerging literature suggesting a role for mechanobiology in the control of
biological functions. In the lung, one can envision cells embedded in a normal ECM
with a certain stiffness that allows for careful regulation of cellular signaling. This
is disrupted in fibrosis where tissue stiffness is greatly enhanced, thereby
promoting differentiation, fibroproliferation and further ECM overexpression.
However, we do not know if nicotine-induced transitional remodeling influences
tissue stiffness. We predict that nicotine-induced transitional remodeling may only
enhance tissue stiffness slightly, but by promoting disrepair and enhanced fibrosis,
it might lead to significant alterations in tissue stiffness after a second insult. We
set out to study this using atomic force microscopy and found increases in lung
tissue stiffness in animals exposed to both bleomycin and nicotine when compared
to those treated with bleomycin alone. These preliminary data needed to be
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confirmed and further investigations will be required to determine the true impact
of transitional remodeling on lung tissue stiffness.
Another important observation made by this work relates to a7 nAChRs, as
these receptors mediated the effects of nicotine in our in vitro and in vivo models.
This is important for two main reasons. First, there are at least 13 nAChRs that
could be targeted, but our studies point to a7 nAChRs, thereby accelerating this
research significantly. Also important is the fact that there are currently clinically
available FDA-approved agents capable of targeting these receptors (e.g.,
Varenicline) and others in development (PNU-282987). Therefore, technology is
already available to develop safe and effective methods of targeting these
receptors if further data confirm that a7 nAChRs are indeed worth targeting for
intervention in fibrosing lung disorders. However, it should be highlighted that a7
nAChRs are present in nearly all cells, ranging from neuronal cells to pulmonary
cells. Thus, targeting this receptor might create problems as other organs are
affected (e.g., brain). Also, how a7 nAChRs modulate intracellular signaling in the
presence of other nAChRs is not entirely clear. Additionally, our data suggest that
absence of a7 nAChRs has unforeseen effects at homeostasis. One explanation
is that its elimination might unveil the roles of other nAChRs which may or may not
be protective in the setting of injury and disrepair. The cholinergic signaling system
is quite complex and further information will be required before these findings could
be exploited at the clinic.
Despite the above, our studies strongly suggest that chronic nicotine
exposure promotes lung tissue remodeling and may enhance inflammation,
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thereby promoting disrepair after injury and fibrosis. Thus, avoidance of tobacco
exposure is important. However, we also found that nicotine has some protective
effects. In our hands, and as observed by others, higher doses of bleomycin
induced mortality. However, nicotine was protective in this setting and this effect
was again mediated via a7 nAChRs. Thus, like a coin, nicotine appears to have
two faces. On one hand, nicotine can promote disrepair after injury, whereas on
the other hand, it can promote survival. This is important as one would need to
dissect these distinct effects to take advantage of the beneficial ones, while
reducing the injurious ones. In our model, we found that nicotine was associated
with alterations in cytokine expression, but other than significant changes in IL-1b,
little was found that could explain the observations made. However, we did
observe an upregulation of superoxide dismutase expression and activity in the
lungs of nicotine-treated animals, and these effects was eliminated in the a7
nAChRs knockout mice. Thus, increased anti-oxidant activity through expression
of SOD might explain the beneficial effects of nicotine on injury-induced death, but
this will require further investigation. Even more convoluting is the fact that recent
data suggest that anti-oxidants might benefit some patients with IPF, while not
having an effect and even worsening outcomes in many others [364, 365]. These
effects are related to genetic variants that influence responsiveness to these
agents (e.g., TOLLIP) [366]. Our data suggests that in patients with such genetic
variants, nicotine might be protective, while it might be detrimental in others.
Further research linking these events to genetic variants will be required before we
can determine the true role of nicotine in fibrosing lung disorders and death.
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Together, our studies help explain the role of smoking in fibrosing lung
disorders, unveil a7 nAChRs as potential targets for intervention, further define the
concept of transitional remodeling, its impact, and reveal how chronic nicotine
exposure might influence multiple systems in ways that promote tissue remodeling.
However, this work would not be useful if this new knowledge cannot be translated
to the clinical arena. To that end, we began to examine ways to detect early
progression of fibrosis. For this, we moved from bench work and animal models to
human data. This retrospective analysis revealed that a new formula based on
variables obtained via regular physiological testing might detect early progression
of fibrosis. This is important for clinical research as many studies evaluating the
impact of novel interventions in lung fibrosis require a significant number of
patients and at least 52 weeks. This explains why these studies typically require a
multi-center approach and tens of millions of dollars for completion. However,
novel approaches capable of identifying disease progression earlier would
potentially decrease the number of subjects required as well as the time needed
to reach a statistically meaningful result. Based on our data, we speculate that the
IMPULSIS and CAPACITY studies, which helped bring the two new anti-fibrotic
drugs to the market, could have been terminated much earlier, perhaps 3-6 months
earlier, thereby decreasing expenses by at least a third. More importantly, this
approach would be extremely helpful at the clinic as clinicians could identify
patients not responding to a particular intervention earlier without the need for
radiologic testing and larger waiting periods.
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One interesting aspect of the new formula is that it predicted early
progression based on the drop of physiological function, but it failed to predict
hospitalization and acute exacerbations. This suggests that deterioration of lung
function is not directly correlated to those other variables of patient outcomes.
Based on these observations, this new formula will need to be tested for several
variables prospectively to determine its true sensitivity and specificity.
In summary, this work provides a foundation for further research directed at
defining the true role of tobacco and how interventions targeting the cholinergic
system might impact fibrosing lung disorders in the clinic (Figure 50).
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Figure 50. Dissertation Summary
Vicary et. Al., Unpublished

Nicotine induces a transitional matrix consisting of increased collagen type I,
fibronectin, and a-SMA expression through a7 nAChRs. This transitional matrix
renders a host susceptible to accelerated pulmonary fibrosis exposed to lung
injury. Alternatively, nicotine induces the anti-oxidant, SOD 1, which appear to
protect against mortality induced by bleomycin-induced lung injury. The promotion
of both remodeling and anti-oxidants is an intriguing idea, because it suggests that
activation of nAChR might decrease oxidative stress, while increasing tissue
remodeling. This interaction may be critical to the pathogenesis of chronic lung
disorders like pulmonary fibrosis characterized by ECM remodeling with low levels
of inflammation. Lastly, including a measure of obstructive airway in the
FEV1/dFVC ratio for measuring IPF progression allows the earlier detection of
idiopathic pulmonary fibrosis progression.
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STRENGTHS AND WEAKNESSES

Strengths
There were several strengths of this dissertation. One strength is the
identification of a transitional matrix as a new potential mechanism mediating
interaction between pulmonary fibrosis and environmental toxicants (i.e., nicotine).
This work describes a characterization of one in vitro and two murine models of
lung injury (acute lung injury and pulmonary fibrosis) after chronic nicotine
exposure. Characterization of these models using a7 nAChR knockout cells and
mice allows for a better understanding of how nicotine-a7 nAChR interaction
affects the lung prior to and after exposure to a secondary injury. The findings of
this study provide rationale to investigate a7 nAChR as a therapeutic target for
clinical treatment, especially with drugs currently in development and FDA
approved (e.g. varenicline and PNU-282987).
Additionally, development and verification of lung decellularization
methodology allows for the investigation of the mechanical properties and integrin
interactions of the lung. Pulmonary fibrosis is marked by pulmonary dysfunction,
which can be further investigated using acellular lungs. Understanding differences
in extracellular matrix composition induced by a pulmonary challenge can provide
new therapeutic targets separate from cells.
Lastly, clinically tracking the progression of pulmonary fibrosis is critical in
patient care and clinical trials. Developing a new non-invasive measure of fibrosis

159

progression allows for improved patient care and shorter clinical trials, save
development costs and accelerated timeline to drugs to receive FDA approval.

Weaknesses

Although several models and approaches were used in this dissertation, it
should be emphasized that most of the studies were based on in vitro and animal
models of lung disease. The model of bleomycin-induced fibrosis is the most
commonly used murine model to investigate pulmonary fibrosis, but it does not
fully capitulate the human disease. The model does not reflect the idiopathic nature
of IPF and given time, bleomycin-induced fibrosis will naturally resolve.
Furthermore, this dissertation focuses on nicotine, one of several thousand
compounds in cigarette smoke. Utilizing nicotine alone, allowed investigation of
specific cellular mechanisms and pathways, but lacks the interactions seen in the
complex chemical composition of cigarette smoke. Additionally, nicotine was
administered via the oral route rather than via inhalation. When inhaled, nicotine
concentrates in the lung before distributing through the bloodstream. This
characteristic was not mimicked by the oral administration used in this dissertation.
Thus, it is not certain if our findings are generalizable to models of smoke inhalation
or if they are relevant to humans. Currently, lungs-on-a-chip systems are being
developed, which will allow for better investigations of the effects of tobacco smoke
on pulmonary cells [367]. In contrast, they might be quite important considering the
emergence of e-cigarettes in younger adults.
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Lastly, despite showing that FEV1/dFVC detected earlier pulmonary decline
when compared to FVC alone, specificity still needs to be verified. This will involve
utilizing CT scans to verify patient loss of FEV1/dFVC is associated with increased
pulmonary fibrosis. This work may end up requiring an increase or decrease in the
10% threshold to be prognostically accurate.
The different approaches used in this dissertation provide a variety of
weaknesses, but together, these can be addressed through future research and
utilizing new methods; some of which are addressed in my future directions.
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FUTURE DIRECTIONS

Pathway of Nicotine Protection

Although this dissertation shows the involvement of a7 nAChRs and Erk,
the pathways by which nicotine induces collagen type I and fibronectin are not
completely elucidated. Whether the same pathway also controls the nicotine
induction of SOD1 is unknown. Additionally, the potential involvement of nicotine
as well as SOD2 and SOD3 need to be investigated. Finding additional pathway
mediators will be important, including potentially, Nrf2. Knockout and
overexpressing mice for the three SODs are available, providing useful tools to
further investigate the role of SODs in acute lung injury.

Integrin Induction of IL-1b

Showing a transitional matrix can induce IL-1b expression through a2
integrin activation is intriguing concept. Investigating this mechanism of
inflammation activation could provide druggable targets. Excessive inflammasome
activation has been associated with neurogenerative and metabolic diseases, but
recent research has also implicated inflammasomes in pulmonary fibrosis [368,
369]. Inflammasome activation drives cleavage of IL-1b to its active, proinflammatory, form. Some research has implicated integrins in the activation with
inflammation. In a murine model of arthritis, blockade of a2b1 integrin decreased
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inflammation and the number of Th17 cells [370, 371]. Additionally, another murine
model of rheumatoid arthritis, knockout of a2b1 integrin reduced basal levels and
blocked TNF-a induction of ERK-1/2 [372]. In airway smooth muscle cells, a2b1
integrin activation mediated IL-1b-dependent secretory responses [373]. Lastly,
a2b1 is not the only integrin worth investigation, with inhibition of the a5b1 integrin
inhibiting NLRP3 expression and IL-1b expression and secretion THP cells [374].

Anti-Oxidant Induction

Another form of oxidant stress is best known as redox stress and can be
measured by evaluating redox potential [375]. Redox stress is created by the
relative concentrations of thiol disulfide couples such as cysteine and cysteine
(Cys/CySS) and glutathione and glutathione disulfide (GSH and GSSG).
Alterations in these thiol disulfide couples result in alterations in redox potential
(Eh). Eh Cys/CySS exerts its main effects extracellularly, while Eh GSH/GSSH is
more relevant intracellularly [376]. nAChRs could also play important roles in
oxidant stress as the Roman lab recently reporting that a4 nAChRs might serve
as sensors of Eh Cys/CySS in lung fibroblasts [377]. Additionally, our group has
also reported that bleomycin-induced lung injury is associated with oxidation of the
Eh Cys/CySS, which stimulates the proliferation of primary lung fibroblasts and
their expression of a-smooth muscle actin and fibronectin, which are also
hallmarks of IPF [378-381].
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Elucidating Complicated Tobacco Smoke

Having evaluated the role of a7 nAChRs in mediating the effects of nicotine,
we have also explored the effects of cigarette smoke extract (CSE) on lung
fibroblasts. As expected, CSE stimulated significant fibronectin protein production
at 6 months (Figure 51 and Figure 52). With the myriad of chemicals in tobacco, it
makes it difficult to elucidate the vast number of changes made by tobacco
exposure, but recently a ‘smoking-lung-on-a-chip’ system has been developed,
which provides a powerful tool to study the effects of whole cigarette and ecigarette smoke on lung cells [382].

Tobacco-related Genetic Changes

Advances in genetic technology have invigorated the focus of the scientific
community on genetic and epigenetic changes driving diseases. The multifarious
composition of tobacco causes a myriad of genetic changes [383]. Our lab is
currently studying epigenetic changes caused by nicotine exposure, which could
help to uncover genetic changes caused by nicotine. These changes could provide
druggable targets with histone acetylators and deacetylators.
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Cancer

Lung fibrosis has been associated with other diseases, including lung
cancer [384]. In the Roman lab, Caleb Greenwell has done some work on the
influence of pulmonary microenvironment on lung cancer, showing increased lung
metastasis in the presence of pulmonary fibrosis (Figure 53) Additionally, over the
course of my Ph.D., I conducted some research on lung cancer, consisting of a
published review of the mammalian target of rapamycin (mTOR) in lung cancer
and the potential for CRKL to mediate epithelial–mesenchymal transition, an
important process in metastasis, in lung cancer (Submitted) [385].
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Figure 51. Cigarette Smoke Induces Fibronectin In Vivo
Roman et. Al. Unpublished

(A) In collaboration with Douglas Arenberg at the University of Michigan, mice were
exposed to tobacco smoke for up to 6 months (see methods). They were then
sacrificed and the lungs processed for immunohistochemistry. A: anti-fibronectin
antibody; B: Control IgG; C and D: Control lungs stained for fibronectin. E and F:
Fibronectin staining in smoke-exposed animals.
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Figure 52. Cigarette Smoke Induces Fibronectin Time-Dependently In Vivo
Roman et. Al. Unpublished

(A) Blinded evaluation of intensity of fibronectin staining at different stages. (B)
Difference in fibronectin staining between control and CSE exposed mice as fold
change. Significance was assessed using p values <0.05 obtained by two-tailed ttest.
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Figure 53. Bleomycin Treatment is Associated with Increased Metastases in
Aged Lungs
Greenwell et. Al. Unpublished

(A) Aged (~9.5 months) mice were treated with PBS or bleomycin followed by
injection with Lewis Lung Carcinoma cells. Lungs were inflated at standard
pressure, fixed in formalin, paraffin-embedded, and sectioned (5 μm) for
histological analysis. Representative images depict PBS- and bleomycin-treated
aged mice at 14x magnification. Tumor metastases are observed in all images
(indicated by arrows), while fibrosis is clear in the bleomycin treated lungs. (B) The
number of lung metastasis was analyzed. Bleomycin instillation in aged animals
increased the number of lung metastases compared to PBS. Significance was
assessed using p values <0.05 obtained by two-tailed t-test.
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ABBREVIATIONS

AEC

Alveolar Epithelial Cells

ELF

Epithelial Lining Fluid

EMT

Epithelial-Mesenchymal Transition

FGF

Fibroblast Growth Factor

HPS

Hermansky-Pudlak Syndrome

HPS-PF

Hermansky-Pudlak Syndrome Associated Pulmonary Fibrosis

IIP

Idiopathic Interstitial Pneumonia

ILD

Interstitial Lung Disease

IPF

Idiopathic Pulmonary Fibrosis

MAPK

Mitogen-Activated Protein Kinase

PDGR

Platelet-Derived Growth Factor Receptor

ROS

Reactive Oxygen Species

SOD

Superoxide Dismutase

TGF-b

Transforming Growth Factor-b

TNF-a

Tumor Necrosis Factor-a

VEGF

Vascular Endothelial Growth Factor
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